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ABSTRACT OF THE DISSERTATION
The Role of Mesenchymal Stromal Cells and Classical Dendritic Cells in the Maintenance and
Regulation of the Bone Marrow Niche
by
Jingzhu Zhang
Doctor of Philosophy in Biology & Biomedical Sciences
Molecular Genetics and Genomics
Washington University in St. Louis, 2018
Professor Daniel Link, Chairperson

The bone marrow niche is an important microenvironment for the regulation of normal and
malignant hematopoiesis. The first discovered niche component is mesenchymal stromal cells,
which are the major source for the production and secretion of multiple niche factors.
Mesenchymal stromal cells are heterogeneous and various transgenes have been used to target
non-identical but overlapping subpopulations. To further characterize the heterogeneity of
mesenchymal stromal cells, we tested the targeting specificity of three tissue-specific Crerecombinase transgenes. We show that in addition to osteoblasts, Ocn-Cre targets a majority of
Cxcl12-abundant reticular (CAR) cells and arteriolar pericytes. Surprisingly, Dmp1-Cre also
targets a subset of CAR cells, in which expression of osteoblast-lineage genes is enriched.
Moreover, a new tissue-specific Cre-recombinase, Tagln-Cre efficiently targets osteoblasts, a
majority of CAR cells, and both venous sinusoidal and arteriolar pericytes. These observations

xi

highlight the heterogeneity of mesenchymal stromal cells in the bone marrow and provide tools
to interrogate this heterogeneity. To further analyze the functional heterogeneity of mesenchymal
stromal cells, we assessed the function of CXCL12 from different subsets of mesenchymal
stromal cells on B lymphopoiesis. We show that CXCL12 from Ocn-Cre targeted stromal cells is
particularly important for the regulation of mature naive B cells and memory B cells, potentially
through the regulation of their homing and/or retention. This suggests that B cell development
requires distinct niches at different stages and Ocn-Cre targeted stromal cells may represent a
specific niche for late-stage B cell development. Besides mesenchymal stromal cells, this thesis
also assesses the function of a recently identified resident population of murine bone marrow
classical dendritic cells (BM cDCs). We show that BM cDC ablation results in a secondary, noncell autonomous loss of BM macrophages. And more importantly, BM cDCs regulate
hematopoietic progenitor and stem cell (HSPC) trafficking through a macrophage independent
pathway, at least in part, through its regulation of sinusoidal CXCR2 signaling and vascular
permeability. These findings suggest BM cDCs may serve as a novel bone marrow niche
component regulating HSPCs. Collectively, this thesis improves on the overall understanding of
the bone marrow niche and provides insights with significant relevance to both basic and clinical
research.

xii

CHAPTER 1: INTRODUCTION TO THE BONE MARROW NICHE,
MESENCHYMAL STROMAL CELLS AND CLASSICAL DENDRITIC CELLS
Hematopoiesis refers to the production of mature blood cells from hematopoietic stem cells
(HSCs) in the bone marrow, which is tightly regulated by both intra- and extra-cellular signals.
Hematopoietic differentiation proceeds through a hierarchical order. Uncommitted and quiescent
HSCs may give rise to proliferative multipotent progenitors, which in turn differentiate into more
restricted progenitors for the production of different hematopoietic lineages1,2. Hematopoietic
differentiation and proliferation are regulated by the bone marrow microenvironment or niche,
which includes different types of niche cells, extracellular matrix, and secreted niche factors3-7.
The concept of the niche was first hypothesized by Ray Schofield in 1978, where he proposed
that a specialized bone marrow niche preserved the ability for stem cells to reconstitute the bone
marrow8. Later, Michael Dexter showed that mesenchymal stromal cell enriched cultures could
maintain primitive hematopoietic cells ex vivo9. Since then, extensive works have been done on
the bone marrow niche, and recent studies have identified multiple niches to regulate different
hematopoietic lineages or different stages during hematopoietic development10-13. Abnormal
hematopoiesis has been associated with multiple diseases, including anemia, blood cancers,
hemorrhagic disorders, infection-related diseases, and immune system regulation-related
diseases14-17. Thus, it is important to study the components and functions of the bone marrow
niche for its regulation of normal and abnormal hematopoiesis. Better understanding of the bone
marrow niche will likely improve our knowledge about the initiation and progression of different
diseases, and may advance the development of more effective treatments.
Prior studies on the bone marrow niche have identified multiple major niche components,
including mesenchymal stem cells, endothelial cells, osteoblast lineage cells, megakaryocytes,
1

macrophages, the sympathetic nervous system, and the main focus of our lab, mesenchymal
stromal cells4-7,10,12,13. Although these components have been shown to regulate the development
and maintenance of hematopoietic progenitor and stem cells (HSPCs), the regulatory
mechanisms and the molecular pathways involved are not fully understood. Mesenchymal
stromal cells are mainly found in the perivascular region, thus also referred to as perivascular
stromal cells, and are the earliest niche component discovered3,9,10,12,18,19. These stromal cells are
the major source for the production and secretion of multiple niche factors, such as stromal
derived factor-1 (SDF-1 or CXCL12) and stem cell factors (SCF or Kit ligand)3,10,11.
Mesenchymal stromal cells are heterogeneous and various markers have been used to
characterize non-identical but overlapping subpopulations, including CXCL12 abundant reticular
(CAR) cells, leptin receptor expressing (LepR+) cells, and Nestin-GFP+ cells3,10,20,21.
Collectively, these stromal cells are critical for maintaining quiescence and promoting
proliferation of HSPCs, so it is important to further characterize its subpopulations for their
potential specific functions and roles in the bone marrow niche.
B cells are an important component of the adaptive immune system whose functions include
antigen presentation and secretion of cytokines and antibodies22. In mammals, B cells mature in
the bone marrow, but also require input from peripheral lymphoid organs23. B cells develop
through a series of different stages which can be identified based on their surface marker
expression24. In the bone marrow, the common lymphoid progenitor (CLP) gives rise to the B
lymphoid progenitor (BLP)25. Dr. Hardy and colleagues have defined the later stages of B cell
development using Hardy Fractions, referred as Fractions A through F26,27. Pre-pro-B cells are
defined as Fraction A cells, which are derived from BLPs and retain most gene expressions of
germline immunoglobulin43. Rearrangement of the heavy chain of immunoglobulin (IgH) starts
2

in early pro-B cells, or Fraction B cells, and is completed in late pro-B cells, or Fraction C
cells43. They then express pre-B cell receptor (pre-BCR), which leads to recombination of the
immunoglobulin light chain, and these cells are defined as Fraction D cells, or pre-B cells26,27.
After light chain rearrangement, these cells are known as Fraction E cells, or immature B cells,
and they express IgM on the surface44. Most immature B cells enter the blood and migrate to the
spleen for maturation into mature naive B cells, or Fraction F cells, expressing both IgM and
IgD26,28-30. Meanwhile, some immature B cells may mature in the bone marrow31. When exposed
to recognized antigens, mature naive B cells further mature in the periphery to become anti-body
secreting plasma cells or memory cells29,30,32. Memory cells may include memory plasma cells
and memory B cells, and studies have suggested the bone marrow as a potential
microenvironment for their maintenance32-36. However, it remains unclear how these cells affect
immune memory and how they are regulated in the bone marrow, which requires further
research.
Dendritic cells (DCs) are found in different tissues with great heterogeneity and functional
variations37-39. Classical or conventional DCs (cDCs) are generally defined as cells with dendritic
morphology and outstanding capacity for presenting antigens and priming T cells40,41. cDCs can
be further divided into two subsets, type 1 cDCs (cDC1s) and type 2 cDCs (cDC2s). cDC1s are
mainly responsible for immune responses against viruses, tumors and intracellular pathogens.
cDC2s are mainly responsible for immune responses against parasites, allergens, extracellular
bacteria, fungi and some intracellular pathogens42. Besides cDCs, studies have also discovered
plasmacytoid DCs (pDCs), which are lymphocyte-like cells specialized in the production of type
I interferons40,43. DCs have a myeloid origin and their development consists of a branch of
hematopoiesis that is different from lymphoid and granulocytic myeloid cell differentiation44. A
3

cell population of clonogenic common DC progenitors (CDP) has been discovered in the bone
marrow (BM), which may differentiate into both cDCs and pDCs45,46. Although cDCs mature in
the peripheral lymphoid organs, clonogenic cDC-restricted progenitors (pre-DCs) have been
found in the spleen (Sp), BM and other tissues47,48, suggesting the capability of cDCs to selfrenew in their resident tissues. Recent studies have shown that BM cDCs mostly reside in the
BM perivascular region, regulating B cells and neutrophils in the bone marrow49-51, although it
remains unknown whether BM cDCs may regulate HSPCs. BM cDCs and BM macrophages are
both mononuclear phagocytes with a common myeloid origin, and recent studies have suggested
BM macrophages may be important for the regulation of HSPCs7,52,53. Thus, it would be
interesting to test whether BM cDCs may function as a novel bone marrow niche component to
regulate HSPCs.

4

1.1. Components of the Bone Marrow Niche
1.1.1. Mesenchymal stem cells
Mesenchymal stem cells (MSCs) are multipotent stromal cells with the capability to
differentiate into osteogenic lineage cells, chondrocytes, and adipocytes4. To identify MSCs, in
vitro colony forming assays can be performed to test whether the cells of interest may form all
three lineages. However, a prior study has identified a population of proliferative osteoblastic
progenitors, MX-1 positive bone marrow stromal cells, which could differentiate into
osteolineage cells, chondrocytes, and adipocytes in vitro yet only differentiate into osteoblasts in
vivo54. Other studies have proposed various markers to identify MSCs in mouse bone marrow,
including platelet-derived growth factor receptor-alpha and -beta (PDGFRα and PDGFRβ),
CD51, Sca1 and alpha smooth muscle actin55-58. But until now, no precise and universal
definition of MSCs exists due to a lack of consensus in defining markers4. Recent studies have
identified Nestin-GFP+ cells that are enriched for MSC activity and express high levels of key
niche factors, such as SCF, CXCL12, PDGFRα, and fibroblast activation protein (FAP)58,59.
Follow-up studies showed that HSCs localize near Nestin-GFP+ cells, and ablation of NestinGFP+ cells leads to bone marrow hypocellularity, anemia, and depletion of osteogenic cells60,61.
Our lab and others have discovered that the Prx1-Cre targeted PDGFRα+ Sca1+ (PαS) cells are
highly enriched for MSCs3. To our surprise, these Prx1-Cre targeted PαS cells did not express
nestin, one possible explanation being that Nestin-GFP transgene does not accurately reflect the
nestin expression in vivo3. Despite the recent research emphasis, the complex population
heterogeneity remains an obstacle for precisely defining the MSC population and studying them
in greater detail.

5

1.1.2. Endothelial cells
HSPCs preferentially localize to the perivascular regions in the bone marrow4,5,62. Prior
studies have shown that BM endothelial cells (ECs) promote HSPC maintenance, and sinusoidal
endothelial cells promote long-term HSC reconstituting capability10,63-66. In addition, BM ECs
have been illustrated to release soluble niche factors, referred as angiocrine function67. CXCL12
and SCF are important niche factors that have been widely investigated in the regulation of
HSPCs in the bone marrow10,68-70. A recent study shows that deletion of Kitl in ECs results in
decreased HSC numbers and reduces the repopulating capability of HSCs after bone marrow
transplantation10. In contrast, later studies using similar models to delete CXCL12 in BM ECs
show minimal decrease in HSPCs and only a modest loss of long-term repopulating capacity of
HSCs after transplantation3,11. Other than secreted niche factors, an EC-specific adhesion
molecule, E-selectin, is shown to activate HSC proliferation71. More recent data suggests that
activation of endothelial CXCR2 by Gro-β (CXCL2) could induce bone marrow vascular
permeability and promote HSPC mobilization72. Another recent study showed that activation of
Notch signaling in ECs results in the up-regulation of cellular SCF level and the expansion of
PDGFRβ+ perivascular mesenchymal cells73. Collectively, these studies provide evidences to
implicate BM ECs as an important component of the bone marrow niche.
BM ECs are heterogeneous, and prior studies have revealed different types of ECs in the
bone marrow74. Sinusoidal capillaries, highly branched small vessels found throughout the
marrow cavity, are the most abundant blood vessels in the bone marrow74. Sinusoidal ECs
express vascular endothelial cadherin (VEcad) and vascular endothelial growth factor receptor-3
(VEGFR3), and are laminin+ or low Sca-1- or low, while arteriolar ECs are mainly laminin+ Sca-1+
VEcad+ Vegfr-3- 75,76. A recent study on the murine postnatal development reveals a novel
6

subtype of blood vessel, type H vessel. These blood vessels express higher levels of endomucin
(Emcn) and CD31 (Pecam1) compared to sinusoidal vessels, and are found in more proliferative
regions of the bone marrow77,78. Distinct bone marrow niches have been proposed around both
arteriolar and sinusoidal vessels12,13,18,79. The arteriolar niche consists of arteriolar ECs and
Nestin-GFPhigh NG2high mesenchymal stromal cells, which are demonstrated to maintain HSC
quiescence12. Arteriolar vessels are less permeable compared to sinusoidal vessels and were
shown to maintain a low level of reactive oxygen species (ROS) in HSCs, while sinusoidal
vessels were shown to be important for regulating HSC trafficking and homing73,79. In
comparison, the sinusoidal niche consisting of sinusoidal ECs and LepR+ (leptin receptor)
mesenchymal stromal cells, was illustrated to regulate both quiescent HSCs and more
proliferative progenitor cells18. So far, it remains unclear whether quiescent HSCs are regulated
by the arteriolar or sinusoidal niche, and it is also possible that both niches may play important
roles to maintain quiescent HSCs. Although the existence and the exact function of arteriolar and
sinusoidal niches are still controversial, it is clear that BM ECs and their surrounding
perivascular niches are critical for the maintenance and development of HSPCs.

1.1.3. Osteoblast lineage cells
Osteoblast lineage cells include osteoblasts, osteocytes and osteoblastic progenitors19,80.
Osteoblasts produce bone matrix proteins and have the potential to differentiate into
osteocytes81. Osteocytes are abundant in bones and are important for bone remodeling,
regulating both osteoblast and osteoclast functions81,82. Osteoblastic progenitors or immature
osteoblasts are bone marrow stromal cells that are likely to differentiate into mature
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osteoblasts19. A recent study showed that transgenic mouse models used previously to study
osteoblasts or osteocytes in fact target other osteoblast lineage cells or mesenchymal stromal
cells19. Thus, it would be more accurate to discuss the roles and functions of osteoblast lineage
cells, instead of each individual, in the bone marrow niche.
Early studies done by Taichman and colleagues show that osteoblast lineage cells support
hematopoietic development and HSC maintenance83,84. Later experiments show that osteoblast
lineage cells are necessary for normal hematopoiesis and HSC activities85,86. In addition,
activation of osteoblast lineage cells has been shown to promote the expansion of phenotypic and
functional HSCs in vivo21,87-89. However, another study suggests that the expansion of osteoblasts
is not sufficient to increase HSC number90. Moreover, a later study shows that defects in
osteoblast function in a murine inflammatory arthritis model are insufficient to impair HSCs91.
While the roles and functions of osteoblast lineage cells on HSPCs remain controversial, recent
study suggests that they may play more important roles for the regulation of lymphoid
progenitors, but not HSPCs11. The differences among these studies may be caused by the
heterogeneity of osteoblast lineage cells, and that different subsets may play different roles in
hematopoiesis92. For example, immature osteoblasts marked by high expression of a
transcription factor, Runx2, may have a greater potential in HSC maintenance and
enhancement93. In contrast, mature osteoblasts and osteocytes that are activated by constitutive
parathyroid hormone (PTH) signaling have a decreased ability to support HSCs, compared to
immature osteoblasts93. Since the common transgenic models used for studying osteoblast
lineage cells lack specificity for a certain cell subset19, it is necessary to develop better markers
or models to further dissect this heterogeneous population and to more accurately study its
function.
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1.1.4. Megakaryocytes
Megakaryocytes (MKs) are hematopoietic lineage cells recognized by their unique
morphology, especially their large size94-96. MKs have been reported to mainly reside in
proximity to bone marrow sinusoids during hematopoietic homeostasis97. Interestingly, after
irradiation, MKs may relocate from the central marrow space to the endosteal surface98. The
same study shows that MKs promote the expansion of the endosteal niche through its production
and release of platelet-derived growth factor-BB (PDGF-BB), thus to increase HSC engraftment
after irradiation98. In fact, one major function of MKs is to release different soluble factors in the
bone marrow99. MKs are the main source of thrombopoietin (TPO) which is important for the
maintenance of quiescent HSCs, and depletion of MKs results in a decrease of intra-BM TPO
concentration and a decrease in HSC number100,101. In addition, MKs are the main source of
platelet factor 4 (PF4 or CXCL4) in the bone marrow that regulates the cell cycle activity to
maintain HSC quiescence102. In contrast, another group has reported an in vitro study in which
MKs release insulin-like growth factor-1 and insulin-like growth factor binding protein-3 to
increase HSC proliferation103. To explain the dual functions of MKs for both maintaining HSC
quiescence and promoting HSC proliferation, Li’s group reported that MKs are the main source
of transforming growth factor β1 (TGF-β1) and fibroblast growth factor-1 (FGF1). While TGFβ1 regulates the quiescence of HSCs during homeostatic conditions, MKs switch to promote
HSC expansion by releasing FGF1 under chemotherapeutic stress6. Collectively, prior studies
have demonstrated that MKs release different soluble niche factors under homeostatic and
stressful conditions, and they serve as an important bone marrow niche component to regulate
both quiescence and proliferation of HSCs.

9

1.1.5. Macrophages
Macrophages are professional phagocytic cells with great heterogeneity, found in both
lymphoid and non-lymphoid tissues38,44,104. Most macrophages are capable of engulfing and
degrading large particles, which allow them to clear foreign and damaged cells23,88,105.
Macrophages are equipped with a broad-range of pattern-recognition receptors (PRRs), which
are required for engulfing cellular debris and pathogenic particles that leads to the production of
inflammatory or immunosuppressive cytokines38,44,104,106. Macrophages are also highly plastic
and can shift their physiology rapidly in response to injury or infection104,107. The phenotypes
and functions of macrophages are largely dependent on the surrounding microenvironment 104.
In general, macrophages can be simply classified into two different types: classically activated,
or M1, macrophages (CAMs), and alternatively activated, or M2, macrophages (AAMs)108.
CAMs are more specialized for antigen presentation, production of nitric oxide (NO), secretion
of chemokines and cytokines, and promoting T-helper 1 (Th1) lymphocytes expansion104,107,108.
Therefore, CAMs play a critical role in the defense against bacteria, although their defense
mechanisms may also damage the host104,108. In contrast, AAMs are involved in the defense
against parasites and fungi 109,110. AAMs express large amounts of cytosolic arginase and
extracellular matrix related proteins, allowing them to regulate inflammation and promote
tissue repair, thus they are also referred to as wound-healing macrophages107,109-111.
Additionally, unique subsets of resident macrophages exist in different tissues, such as brain
microglia, lung alveolar macrophages, and liver Kupffer cells 107,109. Early studies have
suggested that most resident macrophages are derived from circulating monocytes with bone
marrow origin38,104,105,112,113. However, recent studies provide clear evidence that resident
macrophages can proliferate locally in both steady state and stressful conditions, and it remains
10

to be determined whether circulating monocytic precursors or self-renewal is more important
for resident macrophage homeostasis105,114,115. Meanwhile, resident macrophages may also be
classified into CAMs or AAMs, although their response to a given stimulus can be different
from regular CAMs or AAMs 116,117.
Bone marrow macrophages were first discovered in 1958 by ultrastructural study, which
serve as the central component for the erythroblastic island, surrounded by erythroblasts at
different stages of maturation118,119,120. Erythroblastic island macrophages (EIMs) are essential
for the maturation and survival of erythroblasts 119. EIMs produce principal growth factors to
regulate erythropoiesis, such as erythropoietin (EPO)121-123, insulin-like growth factor-1
(IGF1)124,125 and bone morphogenetic protein-4 (BMP4)126. EIMs also contribute to the
synthesis of hemoglobin by incorporating iron into ferritin127. Moreover, EIMs aid in the
enucleation process by phagocytosis and degradation of extruded nuclei 128,129. Another subset
of BM macrophages resides in the endosteal niche and is referred as osteomacs119,130. On
resting bone surfaces, bone lining cells are interspersed by osteomacs, which are in direct
contact with the bone surface 119,131. Osteomacs play an important role in osteoblast formation
and maturation103,115, and can express a wide array of pro-anabolic molecules that are essential
for parathyroid hormone anabolic actions132. Osteomacs may also contribute to injury response
and tissue regeneration through production of growth factors, inflammatory cytokines and
chemokines133,134.
In addition, recent studies reveal that macrophages also localize to the bone marrow
hematopoietic niche and may support other bone marrow niche components in vitro52,131,135.
Prior studies have used different in vivo macrophage depletion models to assess their function
and have shown that macrophage depletion results in the suppression of osteoblast lineage
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cells, reduced expression of important niche factors, HSPC mobilization and marked decrease
of erythroblasts7,52,53,131. In these studies, macrophages regulate HSPCs indirectly through
regulation of osteoblast lineage cells and Nestin + mesenchymal stem cells7,135. Interestingly, a
more recent study suggests that these macrophages may also regulate HSPCs directly, as
CD234 on macrophages stabilizes CD82 on long term (LT)-HSCs to promote quiescence136.
Moreover, BM macrophages express high levels of granulocyte colony stimulating factor (GCSF) receptor137,138, and exposure to the pro-inflammatory factor G-CSF, a commonly used
HSPC mobilizing reagent, substantially reduces BM macrophages52,139. The loss of BM
macrophages then promotes HSCs to proliferate and mobilize, both directly and
indirectly7,135,136,140. Collectively, evidence suggests BM macrophages serve as an important
bone marrow niche component, regulating the quiescence, proliferation and mobilization of
HSPCs under homeostatic and stressful conditions.

1.1.6. The Sympathetic Nervous System
The sympathetic nervous system (SNS) is another important bone marrow niche
component. Prior studies have shown that the SNS regulates HSC mobilization through its
modulation of granulocyte colony stimulating factor (G-CSF) and/or CXCL12 signaling141,142.
Another study suggests that the SNS stimulates Nestin+ mesenchymal cells to send adrenergic
signals to HSPCs143. Meanwhile, non-myelinating Schwann cells are a major source of activated
transforming growth factor β (TGFβ) in the bone marrow144, and TGFβ induces HSC quiescence
ex vivo145. There is evidence that ablation of Schwann cells results in decreased HSC dormancy
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and HSC number146. Therefore, the SNS has been proposed as a major component of the bone
marrow niche.
Collectively, all the components discussed above, as well as mesenchymal stromal cells,
make the bone marrow niche a complicated but critical microenvironment to study.
Understanding the bone marrow niche will not only enhance our knowledge on hematopoiesis,
but it will also help us improve treatments for bone marrow related diseases.

1.2. Mesenchymal Stromal Cells
1.2.1. CAR cells
CXCL12-abundant reticular (CAR) cells are identified by the expression of GFP which is
knocked into the cxcl12 locus147. They have a characteristic reticular morphology, with long
processes extending throughout the bone marrow, and are predominantly perivascular148. In
mouse bone marrow, CAR cells can be defined as Lineage- (CD45, CD31, Ter119 and Gr-1)
stromal cells expressing high levels of GFP19. CAR cells are the main source of bone marrow
CXCL12, and they also express high levels of SCF10,149. A prior study used CXCL12-diphteria
toxin receptor (DTR) mice to deplete CAR cells, which resulted in HSC reduction in the bone
marrow149. Since CAR cells express both CXCL12 and SCF, CXCL12 from CAR cells may not
be necessary for HSC maintenance in the bone marrow. To test this possibility, a later study used
Osterix-Cre (Osx-Cre) and Cxcl12flox models to ablate CXCL12 from CAR cells and found that
CXCL12 expression from CAR cells, while essential for efficient retention of HSPCs in the bone
marrow, was not required for HSC maintenance3.
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CAR cells were originally described as adipo-osteoprogenic mesenchymal progenitors149.
Lineage mapping using Osterix-Cre to target CAR cells shows that both osteoblasts and CAR
cells are targeted, suggesting the osteoprogenic potential of CAR cells3. Meanwhile, Leptinreceptor-Cre (LepR-Cre) targets both CAR cells and adipocytes, which suggests the adipogenic
potential of CAR cells11. While both models target CAR cells efficiently, they target adipocytes
and osteoblasts differently, which brings doubts on CAR cell’s adipo-osteoprogenic potentials.
One possible explanation is that CAR cells may have different adipo-osteoprogenic potentials at
different time points during development, Osx-Cre and LepR-Cre may be turned on at different
stages, thus target adipocytes and osteoblasts differently.
CAR cells have also been reported to affect B lymphopoiesis. A prior study using the
diphtheria toxin-ablation model has shown that CAR cells are important for early B cell
development, as CAR cell ablation results in a loss of CLP, decreased proliferation and increased
apoptosis of pro-B cells148. CXCL12 produced by CAR cells likely plays an important role
during B cell development, as a recent study has demonstrated the effects of ablating CXCL12
from different subsets of CAR cells on B cell development3. In addition, interleukin 7 (IL-7) has
been reported to play an essential role in early B lymophopoiesis150. Deletion of either IL-7 or
IL-7 receptor has been shown to cause reductions in pro-B and pre-B lymphocytes with no
change to pre-pro-B lymphocytes151-153. A recent study crossed IL7-Cre transgenic mice with
Rosa26EYFP mice and illustrated that the IL-7 expressing cells in the bone marrow were
predominantly bipotent CAR cells154.
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1.2.2. LepR+ Cells
LepR+ cells are stromal cells expressing leptin receptor which were originally identified as
Lepr-Cre targeted stromal cells by the Morrison group10. LepR+ cells include more than 90% of
cells expressing high levels of Scf-GFP or Cxcl12-DsRed in young-adult mouse bone
marrow155,156. LepR+ cells are mostly perivascular and especially enriched around sinusoids and
small-diameter arterioles156,157. In normal young-adult mouse bone marrow, LepR+ cells and
CAR cells almost completely overlap with each other155,156. Consistent with this observation, a
later study used Lepr-Cre to conditionally delete Foxc1, a transcription factor that is required
by CAR cells, which resulted into substantial depletion of HSCs and reduced bone marrow
cellularity158. Therefore, LepR+ cells and CAR cells may be considered as the same cell
population, at least in young-adult mice156. Although LepR+/CAR cells only represent
approximately 0.3% of bone marrow cells, their long processes are present throughout the bone
marrow, providing them the capability to affect most bone marrow cells156. LepR+/CAR cells
express both SCF and CXCL12, and are also closely associated with HSCs, thus making them an
important component of the perivascular bone marrow niche3,11,76,155,159.

1.2.3. Nestin-GFP+ Cells
Nestin-GFP+ (Nes-GFP+) cells are bone marrow mesenchymal stromal cells expressing GFP
under the regulatory element of the nestin promoter21,160. Histomorphometry analysis of whole
bone marrow shows two different subsets of Nes-GFP+ cells, according to their expression levels
of GFP and their locations: Nes-GFPdim cells that are perisinusoidal and heavily overlap with
CAR/LepR+ cells; and Nes-GFPbright cells that are periarteriolar and express NG2156,157. A prior
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study done by Frenette’s group used confocal imaging and spatial modeling to reveal that about
35% of HSCs are closely associated with arterioles12. The same study also suggests that these
arteriolar Nes-GFP+ stromal cells and arteriolar niches are indispensable for maintaining HSC
quiescence12. This is in contrast to a later study which shows non-dividing HSCs are mainly
perisinusoidal159.
The concept of the periarteriolar niche was initially based on the suggestion that Nes-GFP+
cells, especially the Nes-CreER and NG2-CreER targeted periarteriolar Nes-GFPbright cells, were
an important source of SCF and CXCL1212,21. Since Nes-GFP+ cells include two distinct subsets,
it is not clear whether the SCF and CXCL12 expressed by Nes-GFP+ cells reflect the expression
by perisinusoidal Nes-GFPdim CAR/LepR+ cells or the expression by periarteriolar Nes-GFPbright
NG2+ cells156. Moreover, inconsistent with the original studies12,21, other groups revealed that
conditional deletion of Cxcl12 and Scf in Nes-CreER and NG2-CreER targeted cells showed no
significant effects on HSC frequency or HSC functions in adult bone marrow10,11,18,155.
Different observations between these groups may be due to the age of mice used in their
experiments. Studies supporting the arteriolar niche administered tamoxifen to deplete Cxcl12
from NG2-CreER or Nes-CreER targeted cells within 3 weeks after birth161,162, when these Cre
alleles are more broadly expressed in the bone marrow163. Other studies administered tamoxifen
6 weeks after birth, when NG2-CreER and Nes-CreER are more restricted to periarteriolar
cells11,159. While the function of Nes-GFPbright NG2+ stromal cells and the concept of the
periarteriolar niche still remain debatable, Nestin-GFP+ stromal cells do represent an important
stromal population in the bone marrow niche.
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1.3. B Lymphopoiesis
1.3.1. CXCL12
CXCL12, also known as stromal-derived factor 1 (SDF-1) was originally discovered as a
chemokine stimulating pre-B cell development in vitro164. CXCL12 is an important chemokine
for hematopoiesis and B lymphopoiesis20, and mice lacking CXCL12 are perinatal lethal with
significant defects in B cell development165. CXCR4 is the primary receptor of CXCL12, and
mice lacking CXCR4 have a defect in early B cell development, with reductions in pre-pro B
cells, CLPs and BLPs166-168. CXCL12 interacts with CXCR4 to activate mitogen-activated
protein kinase (MAPK), PI3 kinase (PI3K), extracellular-signal-regulated kinases (ERK1/2) and
P38169. MAPK activation leads to actin polymerization and the regulation of cytoskeletal change,
and PI3K activation induces polarization of adhesion molecules; both are responsible for the
control of chemotaxis169. In addition, PI3K and ERK1/2 activate the NFkB pathway for gene
transcription to promote cell proliferation, while P38 and PI3K down-regulate pro-apoptotic
factors to inhibit apoptosis and up-regulate anti-apoptotic factors to promote cell survival20,170.
A prior study used transgenic mice to express an intracellular form of CXCL12 to inhibit
CXCL12/CXCR4 signaling by sequestering CXCR4 intracellularly and found defects in B cell
development starting from pro-B cell stage171. The same study showed that extracellular
overexpression of CXCL12 could increase B cell number, further suggesting extracellular
CXCL12/CXCR4 signaling is important for normal B cell development171. In another study, after
being transplanted into irradiated wild type recipients, fetal liver cells from Cxcl12-/- or wild type
mice showed indistinguishable capability to reconstitute the hematopoietic system including B
lymphopoiesis, demonstrating extracellular CXCL12 from the microenvironment, but not from
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hematopoietic cells, is required for B cell development172. In contrast, serial transplantation from
mice reconstituted with Cxcr4-/- fetal liver cells shows a reduction of B cell progenitors in the
bone marrow, illustrating the importance of CXCR4 signaling for efficient B cell
development172. In addition to promoting B cell proliferation, CXCL12/CXCR4 signaling may
also play an important role in regulating B cell retention and trafficking. Transplantation of
Cxcr4-/- fetal liver cells into wild type recipients results in a decrease of B cells in the bone
marrow, but an increase of IgM- B cells in the peripheral blood, indicating a retention defect of B
cell progenitors in the bone marrow173.
In the bone marrow, mesenchymal stromal cells, especially CAR cells, are the main source
of CXCL123,10. However, these stromal cells are heterogeneous and may include different
subsets with more specific functions. The Link lab has used several stromal-specific transgenic
Cre models to delete Cxcl12 from the bone marrow, including Prx1-Cre, Osx-Cre and Ocn-Cre3.
Prx1-Cre and Osx-Cre models, crossed with Cxcl12flox/- mice, induced significant ablation of
CXCL12 in the bone marrow, but Ocn-Cre:Cxcl12flox/- mice did not ablate CXCL12
significantly, compared to Cxcl12flox/- control mice3. Interestingly, Prx1-Cre:Cxcl12flox/-, but not
Osx-Cre:Cxcl12flox/- mice, induced significant reductions in CLPs and BLPs, while both models
had significant reduction in pre-pro B cells3. These observations might be explained by the more
robust ablation of CXCL12 in Prx1-Cre:Cxcl12flox/- mice, compared to Osx-Cre:Cxcl12flox/mice3, suggesting B cell progenitors at different stages may be sensitive to different
concentrations of CXCL12. Another possibility is that the expression of CXCL12 by
mesenchymal stem cells, targeted by Prx1-Cre, but not Osx-Cre, is required for the development
and maintenance of CLPs and BLPs. Collectively, further studies are required to understand the
role of bone marrow stromal CXCL12 in the regulation of B cell development.
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1.3.2. Memory plasma cells
B cells can develop into two major types of memory cells, and they are memory plasma
cells (PCs) and memory B cells. PCs were initially described in 1948174, and were originally
considered as short-lived cells that secrete either IgM or downstream isotypes 32. A later study
identified long-lived PCs in the bone marrow, which are resting in terms of proliferation and
migration, but may produce antibodies of humoral memory32,175. Thus, these cells may also be
referred to as memory PCs. Human PCs generally express high levels of CD38 and CD27, and
low levels of CD20. In mice, the comparable markers are CD138 and B220. To distinguish
memory PCs from short-lived PCs, genes or markers labeling cell cycle and proliferation may be
used, such as Ki67. The bone marrow is the major reservoir for memory PCs, and studies have
suggested that PC progenitors from different lymphoid organs may migrate to the bone marrow
and differentiate into memory PCs32. A prior study has provided some evidence that the
longevity of memory PCs is an intrinsic feature, but extrinsic signals from the surrounding
microenvironment are also required for the survival of memory PCs and the prevention from
apoptosis32,176. In the bone marrow, stromal cells have been strongly suggested to constitute an
important part of the survival niche for memory PCs, either by directly supporting memory PC
survival, or by recruiting and supporting other important niche components. In both human and
mouse, PCs express CXCR4, and CXCL12 produced by stromal cells play a critical role for the
maintenance of memory PCs in the bone marrow32. Disruption of CXCL12/CXCR4 signaling in
the bone marrow may result in a significant loss of bone marrow PCs148. In addition, IL-6
produced by stromal cells has been identified as another important survival factor for memory
PCs. Therefore, it is important to further dissect the stromal cell population and study their
regulation of PCs, especially memory PCs in the bone marrow.
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1.3.3. Memory B cells
Memory B cells are defined as cells that participate in a primary response and persist in the
host after acute immune response. Memory B cells are normally in a resting state and do not
express any effector functions, but upon secondary exposure to the memorized antigen, they
quickly recognize them and produce a faster and stronger immune response32. Memory B cells
differentiate into antibody-secreting PCs upon reactivation, and they are more likely to undergo
PC differentiation compared to naive B cells. Thus, chronic antigen exposure may persistently
reactivate memory B cells to generate more antibody-secreting PCs, which is critical for the
maintenance of long-lived humoral immunity32.
Memory B cells are highly diverse and multiple subsets have been discovered that may
potentially carry different functions for the immune memory32. In humans, memory B cells were
historically identified as immunoglobulin D- (IgD-) B cells, as they had undergone class-switch
recombination177,178. However, a later study identified another subset of IgD+ memory B cells179.
To identify both types of human memory B cells, the same study provides a novel marker, the
tumor necrosis factor (TNF) receptor family member CD27, which is also used nowadays to
mark human memory B cells179. Being a general marker for memory B cells, CD27 cross-links
CD70 to enhance B cell activation in vivo and to favor differentiation towards PCs, resulting in
stronger antibody secretion180-183. CD27+ memory B cells can be further divided into IgM- IgD-,
IgM+ IgD+ and IgM+ IgD- cells, and IgM+ memory cells respond faster to stimulation than naive
cells179,184,185. In addition, more recent studies identify a new subset of memory B cells that are
CD27-, and they are similar to CD27+ memory B cells for carrying somatically mutated
immunoglobulin genes186,187. The identification of murine memory B cells is more complicated,
as CD27 is not a marker for memory B cells in mice188. Due to the heterogeneity of memory B
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cells, simply using surface markers may not provide an accurate method to identify them. A
recent study used the immunization method to induce the production of memory B cells against a
specific antigen, which can be identified by their capability to recognize the specific antigen and
their expressions of conventional memory B cell markers189.
Memory B cells specific for vaccinia virus antigens (smallpox) have been discovered in
humans even 50 years after immunization190. Multiple mechanisms have been shown or
discussed for the maintenance of memory B cells32. A prior study suggests the requirement of an
antigen for the maintenance of the antigen-specific memory B cells191. However, another study
shows that phycoerythrin (PE) specific memory B cells are well persisted in nitrophenyl-chicken
gamma globulin (NP-CGG) immunized mice that have not been exposed to PE192. Other than
antigen dependency, survival and proliferation are other important mechanisms for memory B
cell maintenance32. The spleen has been shown as a major reservoir of memory B cells against
vaccinia virus193. In patients, circulating IgM+ IgD+ CD27+ memory B cells rapidly decline and
finally disappear after splenectomy194. Splenectomy also results in reduced, but not abrogated
circulation of IgD-CD27+ memory B cells after 2 years, suggesting that while the spleen is an
important reservoir for these memory B cells, other organs may also serve as their reservoirs32.
Prior studies have also proposed the bone marrow as a reservoir for memory B cells35,36.
Although a recent study suggests that only a small fraction of memory B cells are BM resident34,
it is possible that these cells may carry unique functions. The bone marrow niche provides a
microenvironment for the maintenance of long-term quiescent HSCs, thus it would be interesting
to test whether these BM memory B cells are more quiescent and may survive in long term, and
to study the potential mechanisms involved in the regulation of these memory B cells by the
bone marrow niche.
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1.4 Dendritic Cells
1.4.1. cDC1
Classical DCs type 1 (cDC1s), also known as CD8α+ cDCs or CD103+ cDCs, were
originally described as a subset of DCs in blood that express high levels of CD141
(thrombomodulin, BDCA-3)195-197. Human cDC1s are a rare population among all cDCs, as they
are only about one-tenth of cDC2s in steady-state blood and tissues42,198-201. cDC1s are found in
both lymphoid and non-lymphoid tissues, and there are suggestions that they are more abundant
in tissues compared to blood, although this idea may need further validation42. While sharing
similar phenotypic markers with cDC2s, cDC1s may be distinguished by their low expression of
CD11c, little expression of CD11b and SIRPα42. Besides, cDC1s express high levels of
CLEC9A, CADM1 and BTLA42. Several gene expression studies have also identified XCR1 as a
conserved marker for cDC1s in many species202. In addition, intracellular IRF8 expression may
be used as a standard marker for identifying cDC1s, as unopposed expression of IRF8 (without
IRF4) defines the lineage198. IRF8 is a transcription factor that play an important role to regulate
the differentiation of DCs, especially cDC1s, at several stages during hematopoiesis through
direct or indirect competition with transcription factors promoting other lineages42,203. IRF8 may
limit granulocytic differentiation, balance DC to monocyte differentiation, compete with IRF4 to
control cDC1:cDC2 output, and maintain cDC1 maturation27,156. Gene dosage of IRF8 is a
critical determinant during DC development. Homozygous deletion of Irf8 causes loss of
monocytes and all DCs, but excessive production of neutrophils204,205. Interestingly, subtle losses
of IRF8 activity in mice only reduces the production of cDC1s206.
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Functionally, cDC1s have been characterized as a subset of DCs with a high intrinsic
capacity to cross-present antigens via MHC I to activate CD8+ T cells and to release IL-12 to
promote T helper type 1 (Th1) and natural killer responses207-210. Expression of XCR1
chemokine receptor by cDC1s enables close interaction with XCL-producing activated T cells
and nature killer (NK) cells27. Human cDC1s efficiently recognize viral and intracellular
antigens, and transport antigens to the appropriate endosomal compartments through several
conserved mechanisms27,211. For example, cDC1s express high levels of CLEC9A, a unique
receptor that recognizes bare actin filaments exposed upon necrotic cell death, thus directs cellassociated antigens into the cross-presentation pathway212-215. cDC1s are also a major source of
type III interferons (IFN), and the production and accumulation of these interferons during
hepatitis C virus infection have been proposed to benefit viral clearance216. In mice, cDC1s have
also been characterized as cross-priming tolerogenic cells, but this potential has not been well
characterized in human217,218.

1.4.2. cDC2
The majority of myeloid cDCs in different tissues and organs are characterized as classical
DCs type 2 (cDC2s), also referred as CD11b+ cDCs, expressing CD1c, CD2, SIRPα and FcεR1
42,197

. Similar to cDC1s, cDC2s also express myeloid surface markers CD13 and CD33, but high

levels of CD11b and CD11c27. A prior transcriptional profiling study has also revealed
CLEC10A, VEGFA and FCGR2A as surface markers of cDC2s199. There is great heterogeneity
among cDC2s found in different tissues, and different subsets of cDC2s may be further
characterized27. Recent studies have characterized human blood cDC2s into two subsets: one
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subset being DC-like with higher expression of CD5, CD1c, HLA-DQ and IRF4; the other subset
being monocyte-like expressing CD14, CD32, CD36 and proportionately higher MAFB219,220.
The development of cDC2s may depend on multiple transcription factors, but unlike cDC1s or
pDCs, no single transcription factor plays an exclusive role to regulate this process197,221-223. In
mice, recent studies have identifed ZEB2 as a factor influencing the fate of pre-DCs towards the
cDC2 lineage and IRF4 as a cDC2 lineage defining factor198,222. Subsets of murine cDC2s exist
in diffent tissues and may depend on variable factors, such as RELB, NOTCH2 and KLF4197. In
contrast, the regulation of cDC2 development in humans is different from mice, and is less
understood. In humans, heterozygous GATA2 deficiency leads to eventual loss of all cDC2s221.
Deletion of IRF8 in humans abrogates entire DC development including cDC2s204,205, while
cDC2s are IRF8-independent in mice224.
cDC2s express a wide range of lectins, TLRs, NOD-like receptors and RIG-I-like receptors,
and may respond to intracellular pathogens, parasites, allergens, fungi and extracellular
bacteria27. CD1a and CD1c expressed by cDC2s may present the glycolipid antigens of
mycobacteria and other pathogens225. Dectin-1 and Dectin-2 are also highly expressed in tissue
cDC2s, which are important for fungal recognition226,227. cDC2s may secrete IL-1, IL-8, IL-10,
IL-12, IL-23 and tumor necrosis factor-α (TNF- α), but little type III interferons, which are
mainly secreted by cDC1s228,229. In addition, in vitro studies have shown that human cDC2s
could activate Type I T helper (Th1), Th2, Th17 and CD8+ T cells182-230. Thus, cDC2s have great
potential to induce a wide range of immune responses in human.
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1.4.3. pDC
Plasmacytoid DCs (pDCs) were first discovered in human tonsil and blood231,232. Different
from myeloid cDCs, pDCs do not express CD11c, CD11b, CD13 or CD33195,196,233. Well-known
markers for human pDCs include CD303 (CLEC4C or BDCA-2), CD304 (BDCA-4), CD85k
(ILT3) and CD85g (ILT7), together with more recently characterized antigens FcεRI, BTLA,
CD358 and CD300A234,235. Transcriptional profiling studies have also identified additional
markers, FAM129C, CUX2 and GZMB199. Development of pDCs depend on the coordinated
process of multiple transcription factors42. The key factors regulating the balance between pDC
and cDC development are E2-2 (TCF4), a basic hemophagocytic lymphohistiocytosis protein,
and its antagonist ID2, a DNA binding inhibitor197,236. TCF4 is the lineage-determining factor for
pDCs and is negatively regulated by ID2237. Recent studies have described multiple transcription
factors to regulate the relative production of pDCs and cDCs, through their interactions with the
TCF4/ID2 signaling pathway42. In humans, heterozygous loss of Tcf4 results in Pitt–Hopkins
syndrome with a pDC deficiency42.
Functionally, pDCs are specialized DCs that detect and respond to viral infections through
the rapid production of large quantities of type I and type III interferons, and the secretion of
cytokines235,238. Toll-like receptor 7 (TLR7) and TLR9 are key receptors for pDCs sensing
single-stranded RNA and double-stranded DNA, respectively235. Interestingly, a prior study has
revealed the potential of pDCs to sense self-nucleic acids239. Together with their prominent role
in the production of type I interferon, pDCs have been implicated in the pathogenesis of
autoimmune diseases including psoriasis and systemic lupus erythematosus240,241. Multiple
studies have also suggested that pDCs are capable of priming CD4+ T cells and CD8+ T cells,
although further studies may be necessary to evaluate their antigen-presenting capacity42.
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Moreover, pDCs have been reported to play conflicting roles in allergy242,243. In addition,
tolerogenic pDCs may be affected by granulocyte-macrophage colony-stimulating factor (GMCSF) to contribute to tumor progression244.

1.5. Summary
The bone marrow niche is a complicated microenvironment that regulates HSPC
maintenance and B lymphopoiesis. Prior studies have identified multiple cellular components of
the bone marrow niche, including mesenchymal stem cells, endothelial cells, osteoblast lineage
cells, megakaryocytes, macrophages, the sympathetic nervous system and mesenchymal stromal
cells. Among these cellular components, mesenchymal stromal cells are particularly of our
interest, which are heterogeneous and serve as the main source of multiple important soluble
niche factors, such as CXCL12, SCF and IL-7. Prior studies in our lab have shown the
importance of stromal CXCL12 expression on regulating B cell development in the bone
marrow. Moreover, BM cDCs have been discovered in the bone marrow that may be important
for the regulation of B cells, suggesting their potential involvement in the bone marrow niche.
Further characterization of the heterogeneity of stromal cells, the role of CXCL12 expression in
different stromal subsets and the role of BM cDCs in the regulation of HSPCs, will improve the
overall understanding on the bone marrow niche and may provide potential targets for future
clinical applications.
In Chapter 2, the heterogeneity of mesenchymal stromal cells will be studied by using
different transgenic Cre models. In Chapter 3, the role of CXCL12 produced by different subsets
of stromal cells will be assessed for their effects on B cell development, especially on the
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maintenance of memory PCs and B cells. In Chapter 4, BM cDCs will be assessed for their
effects on HSPCs by using ablation models, and the potential molecular mechanisms involved in
their regulation of HSPCs will also be studied. Finally, in Chapter 5, these findings on the bone
marrow niche and its regulation of HSPCs or B cells will be summarized and future directions
will be outlined.
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CHAPTER 2: TARGETING OF MESENCHYMAL STROMAL CELLS BY CRERECOMBINASE TRANSGENES COMMONLY USED TO TARGET
OSTEOBLAST LINEAGE CELLS

2.1. Introduction
The bone marrow microenvironment contains a heterogeneous population of stromal cells
that contribute to the regulation of hematopoiesis. Identifying these stromal cells and the signals
they generate has important clinical implications for a number of hematopoietic diseases5,11.
Mesenchymal stromal cells implicated in the maintenance of hematopoietic stem cells (HSCs)
include endothelial cells, osteoblasts, CXCL12-abundant reticular (CAR) cells, mesenchymal
stem cells (MSCs), and arteriolar pericytes3,4,10,12. The use of tissue-specific Cre-recombinase
transgenes to delete genes of interest from defined stromal cell populations is an established and
important technique in the field. Rigorously defining the targeting specificity of the Crerecombinase transgenes is a key to the interpretation of such experiments.
Two Cre-recombinase transgenes that are commonly used to target osteolineage cells are
Ocn-Cre and Dmp1-Cre. Osteocalcin (Ocn, Bglap) is a secreted protein implicated in bone and
glucose metabolism 245. Cell culture and in situ expression studies show that OCN expression is
mostly limited to osteoblasts and osteocytes245,246. This has led to the widespread use of OcnCre transgenes to specifically target osteoblasts and osteocytes247,248. Dentin matrix acidic
phosphoprotein 1 (Dmp1) is expressed in odontoblasts, preosteocytes and osteocytes249,250.
Indeed, a transgene containing an 8 kb regulatory region of Dmp1 linked to GFP results in
osteocyte-specific GFP expression in the bone marrow251. These data have led to the widespread
use of Dmp1-Cre transgenes to specifically target osteocytes, although targeting of some
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osteoblasts also has been observed250,252,253. Furthermore, a study by Kalajzic et al showed that a
10 kb Dmp1-Cre transgene targeted both osteoblasts and osteocytes, as well as a small
population of undefined cells in the bone marrow 250.
In the present study, we used high-resolution microscopy of bone sections and flow
cytometry to carefully define the targeting specificity of Ocn-Cre and Dmp1-Cre in the bone
marrow. We showed that both the Ocn-Cre and Dmp1-Cre transgenes target a much broader
population of bone marrow stromal cells than previously appreciated. We also characterized for
the first time the spectrum of bone marrow stromal cells targeted by a Tagln-Cre transgene. We
show that Tagln-Cre efficiently targets osteoblasts and perivascular stromal cells, but not
endothelial cells.

2.2. Materials and Methods
2.2.1. Mouse strains
Ai9 (B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J) 254 mice and Tagln-Cre (B6.129S6Taglntm2(cre)Yec/J) mice were obtained from The Jackson Laboratory 255. Ocn–Cre mice were a
gift from Thomas Clemens (Johns Hopkins University, Maryland) 256. Cxcl12gfp mice were a gift
from Takashi Nagasawa (Kyoto University, Japan) 257, and Dmp1-Cre mice (containing the 9.6
kb murine Dmp1 promoter) were a gift from Roberto Civitelli (Washington University, MO) 258.
All mice used in this study were 8-10 weeks old. Both male and female mice were used equally
in these studies. Genotyping primers are listed in Suppl. Table 2.1. Mice were maintained under
SPF conditions, and all experimental procedures were performed according to methods approved
by the Animal Studies Committee at Washington University.

29

2.2.2. Flow cytometry
Bone marrow cells were harvested from mouse femurs by first uncapping the ends of the
bone and then centrifuging at 3300 x g for 5 minutes to expel the bone marrow contents. These
cells were then digested with 1.67 mg/ml of type II collagenase (Worthington) in phosphatebuffered saline (PBS) for 12 minutes at 37 °C. Of note, the majority of osteoblasts are not
recovered using this procedure (Suppl. Fig 2.1). The following antibodies were used: CD45 (30F11), CD31 (390), and Ter119 (TER-119). Cells were analyzed on a Gallios flow cytometer
(Beckman Coulter), and data analysis was done using FloJo version 10.0.7 software (TreeStar).
To sort Dmp1-Cre targeted or non-targeted CAR cells, we first isolated platelet-derived
growth factor receptor-beta (PDGFRβ)-positive stromal cells from the bone marrow of Dmp1Cre ROSA26Ai9/+ Cxcl12gfp/+ mice using the AutoMacs Pro Separator system (Miltenyi Biotec)
and a biotinylated anti-PDGFRβ antibody (APB5). Cells were incubated with antibodies against
Gr-1 (RB6-8C5), PDGFRβ (APB5), CD45 (30-F11), CD31 (390), and Ter119 (TER-119) and
then incubated with brilliant violet 421-conjugated Streptavidin (405225, BioLegend). CAR cells
were identified as Cxcl12-GFPbright PDGRRβ+ Gr1- CD45- CD31- Ter119- cells. Dmp1-Cre
targeted CAR cells were tdTomatohigh. Cells were sorted using a MoFlo high-speed flow
cytometer (Dako Cytomation). All antibodies were obtained from eBioscience, unless otherwise
noted.

2.2.3. Immunostaining of bone sections
Mouse hindlimbs were fixed in PBS containing 4% paraformaldehyde, pH 7.4, for 24 hours
at 4 °C. Bones were then decalcified in PBS containing 14% EDTA, pH 7.4, for 7 days at 4 °C.
Following incubation in PBS containing 30% sucrose for 24 hours at 4 °C, bones were
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embedded in Optimal Cutting Temperature Compound (Sakura Finetek). These tissue blocks
were cut into 12 μm sections using a Leica Cryo-Jane system (Leica Biosystems). For
immunostaining, the slides were blocked with 10% donkey serum, diluted in 0.1M Tris-Cl pH
7.5, 150 mM NaCl, and 0.1% Tween 20 (TNT) buffer for 1 hour at room temperature.
Following blocking using the Avidin/Biotin Blocking Kit (SP-2001, Vector Laboratories), slides
were then incubated in primary antibody overnight at 4 °C and, where applicable, they were
incubated with secondary antibody for 1 hour at room temperature. The following antibodies
were used: rabbit anti-NG2 (AB5320, EMD Millipore), rat anti-Sca1 (557403, BD Biosciences),
goat anti-VECadherin (AF1002, R&D Systems), mouse anti-αSMA (1A4, Sigma Aldrich);
AlexaFluor 488-conjugated donkey anti-rat IgG (Jackson Immunoresearch); DyLight649conjugated donkey anti-rat IgG (Jackson Immunoresearch); and biotin-conjugated donkey antigoat IgG (Jackson Immunoresearch). In some cases, slides were then incubated with
streptavidin-DyLight 649 (Jackson Immunoresearch) for 1 hour at room temperature. Finally,
slides were mounted with ProLong Gold antifade reagent with DAPI (Life Technologies).
Images were acquired with a LSM 700 microscope (Carl Zeiss) and processed using Volocity
software (PerkinElmer).
For Hematoxylin & Eosin (H&E) staining, bone sections were air dried for 1 hour and then
incubated with Hematoxylin Gill #3 (GHS316, Sigma-Aldrich) for 5 minutes followed by
incubation with Eosin (HT110132, Sigma-Aldrich) for 3 minutes. Sections were then fixed by
serial five-minute incubations in 50%, 70%, 95%, and 100% ethanol, followed by a five-minute
incubation in xylene. Finally, slides were mounted with Permount mounting medium (Fisher
Chemical). Images were acquired with a LSM 700 microscope (Carl Zeiss).
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2.2.4. RNA expression profiling
RNA was purified from sorted CAR cells using the Qiagen RNeasy Micro Kit (74004,
Qiagen). Libraries were generated using the NuGen Pico SL kit (NuGEN Technologies, San
Carlos, CA) and then hybridized to Affymetrix Mouse Gene 1.0 ST arrays (Affymetrix, Santa
Clara, CA). Gene set enrichment was performed using the GSEA software (Broad Institute).
Differences in gene expression were determined using Significance Analysis of Microarrays
(SAM; Stanford University, Stanford, CA). Expression data has been submitted to Gene
Expression Omnibus, record number GSE81399.

2.2.5. Statistical analyses
Unpaired t-test was used to evaluate the significance of differences between two groups. All
data are presented as mean ±S.D.

2.3. Results
2.3.1. Ocn-Cre targets osteoblasts, a majority of CAR cells, and arteriolar pericytes
To characterize the targeting specificity of Ocn-Cre in postnatal mouse bones, we generated
Ocn-Cre ROSA26Ai9/+ mice and Ocn-Cre ROSA26Ai9/+ Cxcl12gfp/+ mice. The Cxcl12gfp/+
transgene allows for the identification of CXCL12-GFPbright (CAR) cells, which are perivascular
stromal cells in the bone marrow implicated in HSC maintenance 4. The ROSA26Ai9/+ transgene
allows for the identification of Ocn-Cre targeted tdTomato+ cells. Immunostaining of the bone
sections confirmed that the Ocn-Cre transgene efficiently targets osteoblasts (Fig. 2.1A & B,
Suppl. Fig. 2.2) 256. Surprisingly, we also observed that Ocn-Cre targets a substantial fraction of
CXCL12-GFPbright cells (Fig. 2.1A & C). Of note, as expected, no tdTomato+ CAR cells were
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detected in control (Cxcl12gfp/+) mice (Suppl. Fig. 2.3). Flow cytometry showed that Ocn-Cre
targets 72.2 ±4.0% (n = 3 mice) of CXCL12-GFPbright cells (Fig. 2.1D). To assess targeting of
arteriolar pericytes, we stained bone sections from wild type mice with antibodies against alphasmooth muscle actin (αSMA) and NG2 (Fig. 2.2A & B). In these assays, arteriolar endothelial
cells were identified by Sca112, which is also expressed on hematopoietic stem/progenitor cells
but not on CAR cells 3. Whereas αSMA staining was limited to a subset of arteriolar pericytes,
NG2 staining was observed in all arteriolar pericytes (Fig. 2.2A & B). Accordingly, all αSMApositive arteriolar pericytes co-expressed NG2, while only 56.9 ±11.1% (n = 3 mice) of NG2positive arteriolar pericytes co-expressed αSMA. Immunostaining of bone sections from OcnCre ROSA26Ai9/+ mice showed that Ocn-Cre targets 72.2 ±13.3% (n = 3 mice) of NG2-postive
arteriolar pericytes (Fig. 2.2C). Thus, in addition to osteoblasts, Ocn-Cre targets the majority of
CAR cells and arteriolar pericytes in mice.

2.3.2. Dmp1-Cre targets osteoblasts and a subset of CAR cells
To characterize the targeting specificity of Dmp1-Cre in postnatal mouse bones, we
generated Dmp1-Cre ROSA26Ai9/+ mice and Dmp1-Cre ROSA26Ai9/+ Cxcl12gfp/+ mice. As
reported previously253,258, the Dmp1-Cre transgene efficiently targets all osteoblasts (Fig. 2.3A &
B, Suppl. Fig. 2.4). Surprisingly, Dmp1-Cre also targets a subset of CAR cells (Fig. 2.3A & C).
Interestingly, Dmp1-Cre targeted CAR cells were not enriched near the endosteum or
osteoblasts, but were distributed throughout the bone marrow (Suppl. Fig. 2.5A & B). By flow
cytometry 29.2 ±1.7% (n = 3 mice) of CAR cells are targeted by Dmp1-Cre (Fig. 2.3D). In
contrast to Ocn-Cre, NG2+ arteriolar pericytes were rarely targeted by Dmp1-Cre (Fig. 2.3 E).
Thus, Dmp1-Cre targets all osteoblasts and a subset of CAR cells but few arteriolar pericytes.
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To characterize the Dmp1-Cre targeted subset of CAR cells, we sorted tdTomato+ (Dmp1Cre targeted) and tdTomato- CAR cells (non-targeted) and performed RNA expression profiling.
Gene set enrichment analysis showed that Dmp1-Cre targeted CAR cells were highly enriched
for a previously identified group of genes involved in osteoblast maturation or bone development
(Suppl. Fig. 2.6A). Indeed, expression of genes associated with mature osteoblasts such as
Bglap2 (Ocn) and Postn (periostin) are increased nearly 4-fold compared to non-targeted CAR
cells (Fig. 2.3F). In contrast, expression of early osteoblast lineage genes, including Sp7
(osterix) and Runx2 were normal or only minimally elevated (Fig. 2.3F). Expression of key HSC
maintenance genes (Cxcl12, Kitl, and Angpt1) or key B lymphoid factor genes (Igf1, Flt3l, or
BAFF) was similar in Dmp1-Cre targeted and non-targeted CAR cells (Suppl. Fig. 2.6B & C).
However, expression of interleukin-7, which is required for pro-B cell maintenance, was
significantly reduced in Dmp1-Cre targeted CAR cells.

2.3.3. Tagln-Cre targets osteoblasts, a majority of CAR cells, and both arteriolar and
venous sinusoidal pericytes
Arteriolar pericytes have been implicated in HSC maintenance and can be readily identified
in the bone marrow as Nestin-GFPbright or NG2+ periarteriolar cells12. However, a recent study
reported that a substantial number of functional HSCs localize to venous sinusoids in the central
bone marrow159. In an effort to better visualize and isolate sinusoidal pericytes, we tested
targeting by the Tagln-Cre transgene. Tagln encodes for transgelin (SM22a) and is expressed in
smooth muscle cells and cardiomyocytes259-261. Tagln is also expressed in osteoblasts262.
Accordingly, Tagln-Cre targets all osteoblasts (Fig. 2.4A & B, Suppl. Fig. 2.7). Analyzing
Tagln-Cre ROSA26Ai9/+ Cxcl12gfp/+ mice, we observed that Tagln-Cre and CXCL12-GFP mark
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overlapping, but distinct, bone marrow stromal cell populations (Fig. 2.4B & C). Whereas
Tagln-Cre targets the great majority of CXCL12-GFP+ CAR cells that line venous sinusoids
which are marked by VE-cadherin12,13, it does not efficiently target those CXCL12-GFP+ CAR
cells that are not in direct contact with sinusoids (Fig. 2.4D, yellow arrows). Conversely, TaglnCre targets a population of perisinusoidal cells that are CXCL12-GFP-dim/negative (Fig. 2.4D,
red arrows), presumably representing non-CAR venous pericytes. Moreover, Tagln-Cre, but not
CXCL12-GFP, marks periarteriolar pericytes (Fig. 2.4E). Indeed, Tagln-Cre targeted nearly all
NG2+ arteriolar pericytes (Fig. 2.4E & F). Flow cytometry showed that Tagln-Cre targets 74.9
±5.2% (n = 3 mice) of CAR cells (Fig. 2.4G). Conversely, 16.6 ±2.3% (n = 3 mice) of TaglnCre targeted stromal cells were CXCL12-GFP dim/negative. Collectively, these data show that
Tagln-Cre efficiently targets all osteoblasts, a majority of CAR cells and both venous and
arteriolar pericytes.

2.4. Discussion
Ocn-Cre has been widely used to target osteoblasts in past studies 245,247,248. Our data show
that Ocn-Cre targets not only osteoblasts, but also more than 70% of CAR cells and arteriolar
pericytes. CAR cells are mesenchymal progenitors that have adipogenic and osteogenic capacity
in vitro 263. However, only a small subset of CAR cells contributes to osteoblast development in
vivo 4. Whether the Ocn-Cre targeted subset of CAR cells is fated to osteoblast differentiation is
unclear. Of note, we did not observe preferential localization of Ocn-Cre targeted CAR cells to
the endosteal region. CAR cells constitutively produce high levels of multiple cytokines and
chemokines that regulate hematopoiesis, including CXCL12 and stem cell factor 263. Indeed,
CAR cells have been implicated in the maintenance of HSCs and B lymphoid progenitors 264,265.
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Thus, phenotypes reported using Ocn-Cre need to be interpreted in light of our data showing
targeting of CAR cells and arteriolar pericytes, in addition to osteoblasts.
Dmp1-Cre has been widely used to target osteocytes 250,252,266. Several Dmp1-Cre
transgenes have been described. In this study, we show that the 10 kb Dmp1-Cre transgene, not
only efficiently targets osteoblasts, but also a subset of CAR cells. The results are consistent
with a prior study by Kalajzic et. al. showing that the 10 kb Dmp1-Cre transgene targets a small
population of undefined cell in the bone marrow, in addition to osteoblasts and osteocytes 250. Of
note, the same group also reported that an 8 kb Dmp1-Cre transgene, which is thought to be
more osteocyte restricted, targets, at least a subset of, osteoblasts 250. Whether the 8 kb Dmp1Cre transgene targets a subset of CAR cells will require further study. Our data show that the 10
kb Dmp1-Cre transgene targets approximately 30% of CAR cells. Expression profiling of this
subset of CAR cells shows higher expression of genes associated with mature osteoblasts,
suggesting that Dmp1-Cre targeted CAR cells may be enriched for osteoprogenitors. Functional
studies are needed to confirm this possibility.
We report for the first time the spectrum of bone marrow stromal cells that are targeted by a
Tagln-Cre transgene. Prior studies in non-bone tissues had shown transgelin expression in
cardiomyocytes and vascular smooth muscle cells 259-261. Consistent with its expression in
osteoblasts 262, Tagln-Cre efficiently targets osteoblasts. Interestingly, Tagln-Cre appears to
target a majority of CAR cells. Specifically, it targets those CAR cells that are closely associated
with venous sinusoids (i.e., venous sinusoidal pericytes). Conversely, Tagln-Cre does not
efficiently target CAR cells that are more distant from sinusoids. Finally, Tagln-Cre efficiently
targets arteriolar pericytes, which, despite evidence for high CXCL12 expression 12, do not
express high-level GFP in Cxcl12gfp mice. Thus, the Tagln-Cre represents an important new tool
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for investigators to efficiently target both venous sinusoidal and arteriolar pericytes in the bone
marrow.
This study highlights the complexity and heterogeneity of mesenchymal stromal cells in the
bone marrow. Nestin-GFP+, LepR+, and CAR cells represent overlapping but not identical
populations of perivascular mesenchymal stromal cells 4,10,21,265. Bulk cell analysis of each of
these populations shows high-level expression of genes that regulate hematopoiesis, including
factors that regulate HSCs (e.g., kit ligand) and B lymphopoiesis (e.g., interleukin-7) 4,21,264,265.
Our study suggests that there is considerable heterogeneity within the CAR cell population. For
example, the Dmp1-Cre targeted subset of CAR cells, in addition to being enriched for osteoblast
genes, expresses a lower level of interleukin-7 (IL-7). IL-7 producing stromal cells in the bone
marrow are required for the maintenance of Pro-B cells 264, suggesting that Dmp1-Cre targeted
CAR cells likely don’t contribute this specific stage of B cell development.
In summary, we have rigorously defined the targeting specificities in the bone marrow for
the three Cre-recombinase transgenes. Ocn-Cre and Dmp1-Cre target broader stromal cell
populations than previously appreciated, and this data should be incorporated in the design of
future studies. These data further highlight the heterogeneity of mesenchymal stromal cells in
the bone marrow, and suggest that the Cre-recombinase transgenes used in this study could be
used to interrogate this heterogeneity.
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2.7. Figures

Figure 2.1. Ocn-Cre targets osteoblasts and a majority of CAR cells. (A) Composite image
of H & E stained sections from the femur of an Ocn-Cre ROSA26Ai9/+ mouse. (B) Representative
photomicrographs of the metaphyseal region (region “a” in panel A) of a femur section stained
for osteocalcin (green) to mark osteoblasts and DAPI (blue) to highlight nuclei; cells that had
undergone Cre-mediated recombination express tdTomato (red). (C) Representative
photomicrographs taken from the diaphyseal region (similar to region “b” in panel A) of a femur
section from an Ocn-Cre ROSA26Ai9/+ Cxcl12gfp/+ mouse. Cells that express CXCL12 also
express GFP (green). Counterstaining with DAPI highlights nuclei (blue). (D) Representative
dot plots showing GFP and tdTomato expression in lineage (CD45, CD31 and Ter119) negative
stromal cells harvested from Ocn-Cre ROSA26Ai9/+ Cxcl12gfp/+ mice. Original magnification,
200X except for panel A, which is 100X.
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Figure 2.2. Ocn-Cre targets the majority of arteriolar pericytes. Representative
photomicrographs of the diaphyseal region (similar to region “b” in Fig. 1A) of a femur section
from a wild type mouse stained for αSMA (red), NG2 (green), Sca1 (white) and DAPI (blue).
(A) Images showing αSMA+ NG2+ arteriolar pericytes around Sca1+ arteriolar endothelial cells.
(B) Images showing αSMA- NG2+ arteriolar pericytes around Sca1+ arteriolar endothelial cells.
(C) Representative photomicrographs of the diaphyseal region of a femur section from an OcnCre ROSA26Ai9/+mouse stained for NG2 (green) and DAPI (blue). TdTomato (red) represents
cells targeted by Ocn-Cre. Original magnification, 200X.
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Figure 2.3. Dmp1-Cre targets all the osteoblasts and a subset of CAR cells but no arteriolar
pericytes. (A) Composite image of H & E stained sections from the femur of a Dmp1-Cre
ROSA26Ai9/+ mouse. (B) Representative photomicrographs of the metaphyseal region (region “a”
in panel A) of a femur section that was stained for osteocalcin (green) and DAPI (blue). Dmp1Cre targeted cells express tdTomato (red). (C) Representative photomicrographs taken from the
diaphyseal region (similar to region “b” in panel A) of a femur section from a Dmp1-Cre
ROSA26Ai9/+ Cxcl12gfp/+ mouse; cells that express CXCL12 also express GFP (green). (D)
Representative dot plot showing GFP and tdTomato expression in lineage (CD45, CD31 and
Ter119) negative stromal cells harvested from Dmp1-Cre ROSA26Ai9/+ Cxcl12gfp/+ mice. (E)
Representative photomicrographs taken from the diaphyseal region of a femur section from a
Dmp1-Cre ROSA26Ai9/+ Cxcl12gfp/+ mouse stained for NG2 (green) and DAPI (blue). (F) RNA
expression profiling of sorted Dmp1-Cre targeted (tdTomato+) or non-targeted (tdTomato-) CAR
cells was performed. Shown are probe signals for the indicated genes (n = 3 mice). All data
represent the mean ±S.D. *P < 0.05; **P < 0.01 (unpaired t-test). Original magnification, 200X
except for panel A, which is 100X.
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Figure 2.4. Tagln-Cre targets osteoblasts, a majority of CAR cells, and both venous
sinusoidal and arteriolar pericytes. (A) Composite image of H & E stained sections from the
femur of a Tagln-Cre ROSA26Ai9/+ mouse. (B) Representative photomicrographs of the
metaphyseal region (region “a” in panel A) of a femur section that was stained for osteocalcin
(green) and DAPI (blue). (C) Representative photomicrographs taken from the diaphyseal
region (similar to region “b” in panel A) of a femur section from a Tagln-Cre ROSA26Ai9/+
Cxcl12gfp/+ mouse stained for VE-cadherin (white) to mark all endothelial cells; cells that express
CXCL12 also express GFP (green). (D) Enlarged images of the boxed region in panel C. (E)
Representative photomicrographs taken from the diaphyseal region of a femur section from a
Tagln-Cre ROSA26Ai9/+ Cxcl12gfp/+ mouse stained for Sca1 (white) to mark arteriolar endothelial
cells. (F) Representative photomicrographs taken from the diaphyseal region of a femur section
from Tagln-Cre ROSA26Ai9/+ mouse stained for NG2 (green) to mark arteriolar pericytes. (G)
Representative dot plot of lineage (CD45, CD31 and Ter119) negative stromal cells from a
Tagln-Cre ROSA26Ai9/+ Cxcl12gfp/+ mouse showing GFP and tdTomato expression. Original
magnification, 200X except for panel A, which is 100X.

44

2.8. Supplementary Figures

Supplementary Figure 2.1. Osteoblasts remain attached to bone following centrifugation of
femurs. Representative photomicrographs of a femur section from an Ocn-Cre ROSA26Ai9/+
mouse obtained after centrifugation to expel bone marrow contents. Ocn-Cre targeted cells
express tdTomato (red). TdTomato+ cells lining bone are identified as osteoblasts. Nuclei are
highlighted with DAPI (blue). Original magnification, 200X.

45

Supplementary Figure 2.2. Ocn-Cre efficiently targets osteoblasts. Composite image of
representative photomicrographs from an Ocn-Cre ROSA26Ai9/+ mouse. Cells that have
undergone Cre-mediated recombination express tdTomato (red); DAPI (blue) highlights nuclei.
Tdtomato+ cells lining bone are identified as osteoblasts. Original magnification, 100X for all
images.
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Supplementary Figure 2.3. Immunostaining of Ocn-Cre Cxcl12gfp/+ bone sections.
Representative photomicrographs taken from the diaphysis of a femur section from an Ocn-Cre
Cxcl12gfp/+ mouse. GFP (left panel) and tdTomato (right panel) fluorescent signals are shown.
Note, as expected, no tdTomato+ CAR cells are seen in these mice. Original magnification,
200X for all images.
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Supplementary Figure 2.4. Dmp1-Cre efficiently targets osteoblasts. Composite image of
representative photomicrographs from a Dmp1-Cre ROSA26Ai9/+ mouse. Cells that had
undergone Cre-mediated recombination express tdTomato (red); DAPI (blue) highlights nuclei.
Tdtomato+ cells lining bone are identified as osteoblasts. Original magnification, 100X for all
images.
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Supplementary Figure 2.5. Distribution of Dmp1-Cre targeted CAR cells. (A) Composite
image of representative photomicrographs of a femur section from a Dmp1-Cre ROSA26Ai9/+
Cxcl12 gfp/+ mouse (upper left panel). Dmp1-Cre targeted cells express tdTomato (red). Cells that
express CXCL12 also express GFP (green). Counterstaining with DAPI highlights nuclei (blue).
Higher magnifications of the highlighted regions are shown in the upper right and lower left
panels. Original magnification, 100X for all images. (B) Percentage of Dmp1-Cre targeted and
non-targeted CAR cells within a specified distance from the closest osteoblast (OB). Data
represent the mean ±S.D. n = 3 mice.
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Supplementary Figure 2.6. RNA expression profiling of Dmp1-Cre targeted CAR cells.
Dmp1-Cre targeted (tdTomato+) and non-targeted CAR cells (tdTomato-) were sorted from
Dmp1-Cre ROSA26Ai9/+ Cxcl12gfp/+ mice and RNA expression profiling was performed (n=3
mice). (A) Left panel is the gene set enrichment analysis (GSEA) plot showing enrichment for a
previously identified group of osteoblast-lineage genes (p<0.001, FDR = 0.009). The right panel
is a heat map for each gene in this group; red represents higher and blue represents lower
expression. Samples “Dmp1 1, 2 and 3” represent Dmp1-Cre targeted CAR cell samples, while
“CAR 1, 2 and 3” represent non-targeted CAR cell samples. (B) Expression of key genes
associated with HSC maintenance. (C) Expression of key genes that support B lymphopoiesis.
All data are presented as mean ±S.D. *, p-value < 0.05 (unpaired t-test).
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Supplementary Figure 2.7. Tagln-Cre efficiently targets osteoblasts. Composite image of
representative photomicrographs from a Tagln-Cre ROSA26Ai9/+ mouse. Cells that have
undergone Cre-mediated recombination express tdTomato (red); DAPI (blue) highlights nuclei.
Tdtomato+ cells lining bone are identified as osteoblasts. Original magnification, 100X for all
images.
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2.9. Supplementary Table
Primers for the detection of generic Cre transgene in Ocn-Cre and Dmp1-Cre mice.
Primer Name
Cre FOR
Cre REV

Primer Sequence (5’ -> 3’)
GCATTACCGGTCGATGCAACGAGTGATGAG
GAGTGAACGAACCTGGTCGAAATCAGTGCG

Primers for the detection of Cxcl12 gfp transgene.
Primer Name
CXCL12-GFP FOR
CXCL12-GFP mutant REV
CXCL12-GFP wt REV

Primer Sequence (5’ -> 3’)
GGACTGGGAAGATCAAAGGTC
GAACTTCAGGGTCAGCTTGC
GGTGGACCGAGAGTGAAAGT

Primers for the detection of ROSA26Ai9 transgene.
Primer Name
Ai9 wt FOR
Ai9 wt REV
Ai9 mutant REV
Ai9 mutant FOR

Primer Sequence (5’ -> 3’)
AAGGGAGCTGCAGTGGAGTA
CCGAAAATCTGTGGGAAGTC
GGCATTAAAGCAGCGTATCC
CTGTTCCTGTACGGCATGG

Primers for the detection of the Tagln-Cre transgene.
Primer Name
Tagln-Cre FOR
Tagln-Cre wt REV
Tagln-Cre mutant REV

Primer Sequence (5’ -> 3’)
GGCCCAGGGGTTGTCAAAATAGTC
CTCCTCCAGCTCCTCGTCATACTTC
CGCCGCATAACCAGTGAAACAG

Supplementary Table 2.1. Primers for genotyping transgenic mice in this study. “FOR”
means forward primer and “REV” means reverse primer. “mutant” represents the primers used
for the detection of a transgene and “wt” represents the primers used for the detection of the
wild type allele at the corresponding locus for that transgene.
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CHAPTER 3: CXCL12 FROM OCN-CRE TARGETED BONE MARROW
STROMAL CELLS REGULATES LATE-STAGE B CELL DEVELOPMENT

3.1. Introduction
CXCL12 is a common chemokine found in the bone marrow that is important for the
regulation of B lymphopoiesis. CXCL12 interacts with its main receptor, CXCR4, to activate
multiple signaling pathways responsible for the control of chemotaxis, cell proliferation and cell
survival20,169,170. In the bone marrow, mesenchymal stromal cells, especially CAR cells are the
main source of CXCL123,10. CAR cells are a heterogeneous population and previous studies have
tested multiple transgenic Cre mouse models for targeting different subsets of CAR cells3,19.
Among these Cre models, Prx1-Cre and Osx-Cre target nearly all CAR cells, while Prx1-Cre
targets additional mesenchymal stem cells3. In contrast, Ocn-Cre and Dmp1-Cre targets around
70% and 30% of CAR cells, respectively19. A prior study has suggested the specific role of
Dmp1-Cre targeted CAR cells as being enriched for potential osteoprogenitors, but the specific
functions of Ocn-Cre targeted CAR cells have not yet been discussed19.
In humans and mice, B lymphopoiesis mainly occurs in the bone marrow, with the
additional requirement of peripheral lymphoid organs23. B cell development undergoes a
stepwise progression of stages which can be identified based on surface marker expression24.
Hardy Fractions have been extensively used to identify different stages of B cells, and Fraction F
describes the last stage of B cell development before maturation, the mature naive B cells that
express IgD26,28-30. In response to stimulation, such as antigen exposure, mature B cells will
further differentiate into anti-body secreting plasma cells (PCs) or memory cells32. Memory cells
may include memory B cells and memory PCs, also known as long-lived PCs, both have been
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suggested to potentially reside in the bone marrow32-36. So far, only limited research has been
done to study the functions and regulations of mature naive B cells, memory B cells and memory
PCs in the bone marrow.
In the present study, we used different transgenic Cre models to test the regulation of B cell
development by CXCL12 from different subsets of stromal cells. We show that CXCL12
expressed by Ocn-Cre targeted stromal cells may be specifically important for the regulation of
mature naive B cells and memory B cells in bone marrow. Collectively, data from this study may
provide insight into the complex relationships between different stromal cell populations and
may improve our understanding of the regulation of B lymphopoiesis and immune memory in
the bone marrow by CXCL12.

3.2. Materials and Methods
3.2.1. Mouse strains
Cxcl12flox mice were generated as previously described3. Prx1-Cre (B6.Cg-Tg(Prrx1cre)1Cjt/J) mice, Osx-Cre (B6.Cg-Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/J) mice, CAG-GFP
(Tg(CAG-GFP*)1Hadj/J) mice, IgHa/J (B6.Cg-Gpi1a Thy1a Igha/J) mice and Ai9 (B6.CgGt(ROSA)26Sortm9(CAG-tdTomato)Hze/J) 254 mice were obtained from The Jackson Laboratory 255.
Ocn–Cre mice were a gift from Thomas Clemens (Johns Hopkins University, Maryland) 256.
Cxcl12gfp mice were a gift from Takashi Nagasawa (Kyoto University, Japan) 257, and Dmp1-Cre
mice (containing the 9.6 kb murine Dmp1 promoter) were a gift from Roberto Civitelli
(Washington University, MO) 258. Cxcl12+/- mice were obtained through the RIKEN
BioResource Center (Ibaraki, Japan). All mice used in this study were 8-10 weeks old. Both male
and female mice were used equally in these studies. Mice were maintained under SPF
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conditions, and all experimental procedures were performed according to methods approved by
the Animal Studies Committee at Washington University.

3.2.2. Immunostaining of bone sections
Femurs and tibias were harvested from mice and fixed overnight in 10% formalin (SigmaAldrich) at 4oC. Fixed bones were then washed twice in PBS, followed by decalcification in 14%
ethylenediaminetetraacetic acid (EDTA) pH 7.4 solution for 7 days. Decalcified bones were then
incubated in 30% sucrose in PBS overnight at 4oC. These bones were then snap frozen in
optimum cutting temperature (OCT) medium (Tissue-Tek) in Cryomold (Tissue-Tek). Frozen
blocks were sectioned using the Cryostat system (Leica Biosystems). Sections were then
processed using standard immunofluorescent staining protocol. Antibodies used for
immunofluorescent staining included: goat anti-mouse VE-Cadherin (R&D Systems AF1002),
rat anti-mouse IgD (BD Biosciences clone 11-26c.2a), rat anti-mouse B220 (BD-Biosciences,
RA3-6B2), and rat anti-mouse IgM (eBioscience II/4). In the end, slides were mounted with
Prolong Gold Antifade Reagent (Invitrogen) and were sealed with nail polish. Slides were
imaged using a LSM 700 confocal microscope and ZEN imaging software (Zeiss).

3.2.3. Flow Cytometry
Bone marrow cells were harvested from mouse femurs by first uncapping the ends of the
bone and then centrifuging at 3300 x g for 5 minutes to expel the bone marrow contents. Spleen
cells were harvested from mouse spleen by crushing spleen and filter the cells through a 22um
strainer. Cells were stained by standard protocols with the following antibodies (eBiosciences
unless otherwise noted): CD3e (145-2C11), CD4 (L3T4), CD8a (53-6.7), CD11b (M1/70),
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CD45R (RA3-6B2, B220), CD11c (N418), Flk2 (A2F10), CD27 (LG.7F9), Gr-1 (RB6-8C5,
BioLegend), IL-7Ra (gift of Deepta Bhattacharya, Washington University), Ly6D (49-H4, BD
Biosciences), NK1.1 (PK136), IgM (II/4), IgD (11-26c), CD19 (eBio1D3), CD43 (S7, BD
Biosciences), TER-119, CD45 (30-F11), CD31 (390), CD80 (16-10A1, BioLegend), CCR6 (292L17, BioLegend). NP (4-Hydroxy-3-nitrophenylacetyl hapten) (Biosearch Technologies) was
conjugated with Allophycocyanin (APC) to form NP-APC (gift of Deepta Bhattacharya,
Washington University). Cells were analyzed on a Gallios flow cytometer (Beckman Coulter),
and data analysis was done using FloJo version 10.0.7 software (TreeStar).

3.2.4. Quantitative real-time PCR
To collect total bone marrow RNA, tibias from mice were flushed with 1 mL of Trizol
(Invitrogen) and RNA was extracted following the manufacturer’s instructions. cDNA was
prepared using iScript cDNA Synthesis Kit (Bio-Rad). Quantitative real-time PCR (qRT-PCR)
was then performed using the TaqMan Universal RT Master Mix (Applied Biosystems), with no
template and no RT controls. Data was collected on a OneStep Real-Time PCR System (Applied
Biosystems). Primers were:
CXCL12 forward, 5’GAGCCAACGTCAAGCATCTG-3’;
CXCL12 reverse, 5’-CGGGTCAATGCACACTTGTC-3’;
CXCL12 dT-FAM/TAMRA probe, 5’-TCCAAACTGTGCCCTTCAGATTGTTGC-3’;
β-actin forward, 5’-ACCAACTGGGACGATATGGAGAAGA-3’;
β-actin dT-VIC/TAMRA probe, 5′-AGCCATGTACGTAGCCATCCAGGCTG-3′.
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3.2.5. Mature B cell homing assay
Spleens were harvested from 8-12 week old CAG-GFP mice, and were then crushed and
filtered through a 22um cell strainer. 5 million splenocytes were injected into Cxcl12flox/- or OcnCre: Cxcl12flox/- mice, through retro-orbital injection. Recipient mice were then harvested 24
hours after transplantation to collect bone marrow and spleen using the same method as
described earlier. GFP+ mature naive B cell number was quantified via flow cytometry.

3.2.6. Primary and secondary immunization
Ocn-Cre:Cxcl12flox/flox or Cxcl12flox/flox mice were immunized with a mixture of 100µg NPCGG (Chicken Gamma Globulin) (Biosearch Technologies) and 100µl of aluminium hydroxide
gel adjuvant (Alhydrogel) (InvivoGen), through intraperitoneal injection. The enzyme-linked
immunosorbent assay (ELISA) was then performed to test primary immune response. Immune
memory was measured 2 weeks after primary immunization. For secondary immunization, 20
million donor cells from NP-CGG immunized Ocn-Cre:Cxcl12flox/flox or Cxcl12flox/flox mice were
transplanted into IgHa/J recipient mice without irradiation, through retro-orbital injection. One
day after transplantation, 50µg of NP-CGG was injected into these recipient mice, through retroorbital injection. Secondary immune response was then measured with ELISA.

3.2.7. Enzyme-linked immunosorbent assay (ELISA)
ELISA plates were coated with 5µg/ml NP (18)-BSA protein, or 5µg/ml BSA as control,
overnight at 4 ºC. Then, block the ELISA plates with ELISA blocking buffer (PBS + 2%BSA +
0.05% Tween20) at 37 ºC for 1 hour. Wash plates, add diluted serum samples, serially diluted
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standard controls or negative controls into ELISA plates, incubate at room temperature for 2
hours. For primary immune response, add anti-mouse IgM antibody (Life Technologies) and
incubate at room temperature for 1 hour. Wash plates, then add HRP-goat anti-mouse IgM (Life
Technologies) and incubate at room temperature for 1 hour. Then, develop the plate in TMB
solution (eBioscience) and stop the reaction with stop buffer (eBioscience). Read the plates at
450nm wavelength, using an Epoch Microplate Spectrophotometer (BioTek).
For measuring secondary immune response, after incubating the plate with serially diluted
serum samples, add biotinylated anti-IgG1b (BD Pharmingen) or biotinylated anti-IgG1a (BD
Pharmingen) antibodies into the plates, incubate at room temperature for 1 hour. Wash plates,
add streptavidin-HRP (BD Pharmingen), incubate at room temperature for 1 hour. Then, use the
same protocol as for measuring primary immune response to develop the plates.

3.2.8. Statistical analyses
Statistical significance was determined using Prism software (GraphPad). Unless otherwise
indicated, unpaired t-test or 1/2-way ANOVA analyses were used to evaluate the significance of
differences between two or multiple groups. All data are presented as mean ±SEM.
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3.3. Results
3.3.1. Ocn-Cre targeted stromal cells regulate mature naive B cells in bone marrow
To assess the role of CXCL12 expressed by different subsets of bone marrow stromal cells
in B cell lymphopoiesis, we previously crossed different transgenic Cre models with Cxcl12flox/mice (experiments done by Ryan Day). Prx1-Cre was used to ablate CXCL12 from nearly all
bone marrow stromal cells as it targets mesenchymal stem cells and their downstream progeny,
including CAR cells, osteoblasts and osteocytes3. As expected, ablation of CXCL12 in Prx1-Cre
targeted stromal cells significantly reduced the mRNA level of CXCL12 to a minimal level in
the bone marrow (Fig. 3.1A). Meanwhile, we observed significant decrease in white blood cells
(WBCs) and all stages of B cells during B lymphopoiesis in the bone marrow (Fig. 3.1B-J). OsxCre was used to target CAR cells and their downstream progeny, including osteoblasts and
osteocytes3. Ablation of CXCL12 in Osx-Cre targeted stromal cells resulted in a significant
reduction of CXCL12 mRNA level, but to a lesser extent compared to Prx1-Cre:Cxcl12flox/model (Fig. 3.1A). Similar to Prx1-Cre:Cxcl12flox/- mice, we observed significant decrease in
WBCs and total B cells, as well as in other stages during B cell development, except in common
lymphoid progenitors (CLPs) and B lymphoid restricted progenitors (BLPs) (Fig. 3.1B-J). This is
consistent with our previous finding that CXCL12 expressed by Prx1-Cre targeted mesenchymal
stem cells is important for the development and maintenance of CLPs and BLPs3. Ocn-Cre
targets ~70% of CAR cells, all osteoblasts and arteriolar pericytes19. Interestingly, ablation of
CXCL12 in Ocn-Cre targeted cells resulted in a mild, but non-significant reduction of CXCL12
mRNA level (Fig. 3.1A). Moreover, Ocn-Cre:Cxcl12flox/- mice showed no significant decrease of
WBCs, total B cells and most stages of B cell development, except mature naive B cell or
Fraction F cells (Fig. 3.1B-J). To address the question whether the mild decrease of CXCL12 in
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Ocn-Cre:Cxcl12flox/- mice may affect mature naive B cells, we further examined Prx1Cre:Cxcl12flox/+ mice. Our data shows that the two models have nearly the same expression
levels of CXCL12, but Ocn-Cre:Cxcl12flox/- mice have a significantly lower number of mature
naive B cells (Fig. 3.1K&L). Collectively, these data suggests that CXCL12 from Ocn-Cre
targeted cells may play a specific role in the regulation of mature naive B cells in the bone
marrow.
To more specifically assess the role of CXCL12 expressed by Ocn-Cre targeted cells, we
further generated Ocn-Cre:Cxcl12flox/flox mice. In these mice, we observed a significant, but mild
reduction of CXCL12 mRNA level, compared to Cxcl12flox/flox control mice (Fig. 3.2A).
Meanwhile, we observed significant decrease of mature naive B cells, while other stages of B
cell development remain unchanged (Fig. 3.2B). Dmp1-Cre targets ~30% of CAR cells, all
osteoblasts and few arteriolar pericytes19. In Dmp1-Cre:Cxcl12flox/flox mice, we observed no
significant decrease in CXCL12 mRNA level and all stages of B cell development (Fig.
3.2C&D). Comparing data from Dmp1-Cre:Cxcl12flox/flox and Ocn-Cre:Cxcl12flox/flox mice, it
suggests that the expression of CXCL12 by osteoblasts plays little role in the regulation of
mature naive B cells, and Ocn-Cre targeted stromal cells specifically regulate mature naive B
cells through their expression of CXCL12.

3.3.2. CXCL12 expression in Ocn-Cre targeted stromal cells regulates the homing and/or
retention of mature naive B cells in the bone marrow
Mature naive B cells were mostly developed in the spleen and some of them home back to
the bone marrow26,28-30. In Ocn-Cre:Cxcl12flox/- mice, the number of mature naive B cells in the
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spleen was comparable to the Cxcl12flox/- control mice (Fig. 3.3A). This observation suggests that
the loss of mature naive B cells in the bone marrow of Ocn-Cre:Cxcl12flox/- mice is not likely due
to a defect in peripheral maturation. To examine the homing and/or retention of mature naive B
cells in the bone marrow, we transplanted splenocytes from CAG-GFP donor mice that
ubiquitously express GFP into Ocn-Cre:Cxcl12flox/- mice or Cxcl12flox/- control mice (Fig. 3.3B).
After 24 hours, the recipient mice were harvested and the number of GFP+ mature naive B cells
was quantified in both bone marrow and spleen, using flow cytometry (Fig. 3.3C&D). While
there was no significant difference in spleen (Fig. 3.3C), the number of GFP+ mature naive B
cells was significantly reduced in the bone marrow of Ocn-Cre:Cxcl12flox/- mice (Fig. 3.3D).
Collectively, these data demonstrate that CXCL12 expression in Ocn-Cre targeted stromal cells
plays an important role in the regulation of homing and/or retention of mature naive B cells in
the bone marrow.

3.3.3. Ablation of CXCL12 in Ocn-Cre targeted stromal cells did not affect bone marrow
plasma cells and primary immune response
Other than Hardy fractions of B cells during different developmental stages, plasma cells
(PCs) and memory B cells, two terminal stage B cells have also been found in the bone
marrow32,35,36. To assess the effects of stromal CXCL12 ablation on plasma cells in the bone
marrow, femurs from Ocn-Cre:Cxcl12floxflox- mice and Cxcl12flox/flox control mice were harvested
and analyzed. Using flow cytometry, we discovered no significant difference after stromal
CXCL12 ablation, for the numbers of IgM+ or IgG+ PCs, defined as B220+ CD138+ cells (Fig.
3.4A&B). To functionally assess the effects of stromal CXCL12 ablation on PCs, we examined
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the humoral immunity after antigen exposure in the two groups of mice. Ocn-Cre:Cxcl12floxfloxmice and Cxcl12flox/flox control mice were immunized with NP-CGG (1:19 ratio), and we
quantified the humoral immune response by measuring the amount of NP-specific IgM
antibodies in blood serum using ELISA. At different time points, we found no significant change
on the NP-specific IgM levels in blood serum after stromal CXCL12 ablation (Fig. 3.4C).
Collectively, these data suggests that the ablation of CXCL12 in Ocn-Cre targeted stromal cells
does not affect the number of PCs in the bone marrow and the humoral immunity.

3.3.4. Ablation of CXCL12 in Ocn-Cre targeted stromal cells reduces the number of
memory B cells in the bone marrow
To assess the effects of CXCL12 ablation in Ocn-Cre targeted stromal cells on memory B
cells, we immunized Ocn-Cre:Cxcl12floxflox- mice and Cxcl12flox/flox control mice with NP-CGG
(1:19 ratio). Two months after immunization, we quantified the number of NP-specific memory
B cells in the bone marrow using flow cytometry. NP-specific memory B cells were defined as
NP+ Lin- B220+ IgM- IgD- CCR6+ CD80+ cells, and we observed a significant reduction of the
memory B cells when CXCL12 was ablated in the bone marrow (Fig. 3.5A). In addition, we
quantified the number of NP-specific memory B cells in the spleen from the same mice and
found no significant differences (Fig. 3.5B). Collectively, these data demonstrates the
importance of CXCL12 expressed by Ocn-Cre targeted stromal cells in the regulation of memory
B cells in the bone marrow.
To our surprise, a population of NP+ Lin- B220+ IgM+ IgD+ CCR6+ CD80+ cells was found
in the bone marrow whose number was decreased in Ocn-Cre:Cxcl12floxflox- mice, compared to
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Cxcl12floxflox-control mice (Fig. 3.5C). Same population was also found in the spleen, but had no
decrease when stromal CXCL12 was ablated (Fig. 3.5D). The potential existence of IgM+ IgD+
memory B cells was previously discussed by other studies179,184,185. To test whether these cells
may carry similar functions as the conventional memory B cells that are IgM- IgD-, we assessed
the secondary immune response generated from these cells. Wildtype mice were immunized with
NP-CGG to generate memory B cells and we collected unenriched cells, IgM+ and IgD+ enriched
cells (including IgM+ IgD+ cells), and IgM- IgD- enriched cells from these mice at 2 months post
immunization. All three samples of cells were then transferred into IgHa/J recipient mice through
retro-orbital injection, followed by secondary immunization of NP-CGG one day after transplant.
IgHa/J mice only express IgG1a but not IgG1b which is the only isotype expressed by the donor
mice. One week after secondary immunization, ELISA was used to quantify the amount of NPspecific IgG1b in these recipient mice to estimate the secondary immune response generated
from the donor memory cells. Our preliminary data showed that IgM+ and IgD+ enriched cells
from both bone marrow and spleen could not generate significant secondary immune response,
suggesting IgM+ IgD+ cells play little role in the B cell immune memory (Fig. 3.5E).

3.4. Discussion
We have previously shown the importance of CXCL12 in the regulation of B lymphopoiesis
in the bone marrow3. We have demonstrated the requirement of CXCL12 expression from
mesenchymal stem cells for the maintenance of CLPs and BLPs, while CXCL12 expression from
CAR cells are not required for early B lymphopoiesis until pre-pro-B cell stage3. This study
further characterizes the role of CXCL12 expression from different subsets of stromal cells on B
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lymphopoiesis. Our data shows that CXCL12 expression from Ocn-Cre targeted cells are
specifically important for the maintenance of mature naive B cells. We also ablated CXCL12 in
Dmp1-Cre targeted cells and found no effects on mature naive B cells or other B cell
compartments. A prior study has shown that both Ocn-Cre and Dmp1-Cre targets nearly all
osteoblasts, and about 70% or 30% of CAR cells, respectively19. Moreover, Ocn-Cre, but not
Dmp1-Cre, targets arteriolar pericytes19. Thus, CXCL12 expression by Ocn-Cre targeted stromal
cells, but not osteoblasts, regulates mature naive B cells. To further understand this regulation,
we examined the homing and/or retention of mature naive B cells in Ocn-Cre:Cxcl12flox/- mice,
and observed a significant defect, compared to the control mice.
In addition, we also examined the effects of CXCL12 ablation in Ocn-Cre targeted stromal
cells on two end-stage B cells, plasma cells and memory B cells in the bone marrow. We
observed no significant decrease of plasma cells in Ocn-Cre:Cxcl12flox/flox mice, while IgM- IgDNP-specific memory B cells were significantly reduced. To confirm this finding, further
experiments will be performed to test whether there is a functional defect of NP-specific immune
memory in the bone marrow. Interestingly, we also discovered an IgM+ IgD+ NP-specific B cell
population in the bone marrow, expressing similar markers as the conventional memory B cells.
To test the function of these cells, we performed secondary immunization and assessed the
secondary immune response generated by these cells. Our data suggests that these cells play little
role in the generation of secondary immune response, and their functions remain unclear.
In conclusion, our data show that CXCL12 expression by Ocn-Cre targeted stromal cells
may specifically regulate mature naive B cells and memory B cells. This study provides further
evidence to support the functional heterogeneity of bone marrow mesenchymal stromal cells,
which may improve our knowledge on the regulation of the bone marrow niche. Meanwhile,
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better understanding of the regulation of B lymphopoiesis and B cell derived immune memory
may provide targets with clinical relevance, contributing to the development of potential
therapies against different diseases involved in the bone marrow.
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3.7. Figures
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Figure 3.1 CXCL12 expression by stromal cells is important for B lymphopoiesis. A.
Cxcl12flox/-(flox/-), Ocn-Cre:Cxcl12flox/- (Ocn flox/-), Osx-Cre:Cxcl12flox/- (Osx flox/-) and Prx1Cre:Cxcl12flox/- (Prx1 flox/-) mice were flushed with Trizol to extract total bone marrow RNA,
which was then used for RT-qPCR. mRNA level of CXCL12 was normalized to β-actin. B-J.
Femurs from four groups of transgenic mice were harvested and analyzed for different cells
populations using flow cytometry. Cell populations include: white blood cell (WBC) (B),
common lymphoid progenitor (CLP) (C), B lineage restricted progenitor (BLP) (D), total B cell
(E), pre-pro B cell (F), pro-B cell (G), pre-B cell (H), immature B cell (I) and mature naive B
cell (J). Sample size, n = 5-37 mice per group in all experiments. K&L. Prx1-Cre:Cxcl12flox/+
(Prx1 flox/+) mice were also examined and compared with Ocn flox/- group for CXCL12
expression (K) (n = 7 or 12 mice, respectively) and the number of mature naive B cells (L) (n =
10 or 21 mice, respectively). Data represent the mean ±SEM, *P < 0.05; **P < 0.01; ***P <
0.001; ****P<0,0001; “ns” means non-significnat, compared to Cxcl12flox/- control mice unless
otherwise indicated.
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Figure 3.2. CXCL12 expression in Ocn-Cre targeted stromal cells is important for the
regulation of mature naive B cells. A&C. Tibias from A. Ocn-Cre:Cxcl12flox/flox (Ocnflox/flox), C. Dmp1-Cre:Cxcl12flox/flox (Dmp1-flox/flox), and Cxcl12flox/flox (flox/flox) mice were
flushed with Trizol to extract total bone marrow RNA, which was then used for RT-qPCR.
mRNA level of CXCL12 was normalized to β-actin. B&D. Femurs were harvested from OcnCre:Cxcl12flox/flox mice (B), Dmp1-Cre:Cxcl12flox/flox mice (D), and Cxcl12flox/flox control mice
(B&D). Bone marrow from the femurs were then analyzed using flow cytometry to quantify the
number of B cells during different developmental stages. Sample size, n = 3-6 mice per group in
all experiments. Data represent the mean ±SEM, **P < 0.01; ***P < 0.001, compared to
Cxcl12flox/flox control mice unless otherwise indicated.
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Figure 3.3. CXCL12 expression in Ocn-Cre targeted stromal cells regulates the homing
and/or retention of mature naive B cells in the bone marrow. A. The number of mature naive
B cells in the spleen from Cxcl12flox/-(flox/-) and Ocn-Cre:Cxcl12flox/- (Ocn flox/-) mice, were
quantified using flow cytometry. B. 5 x 106 splenocytes from CAG-GFP mice were transplanted
into Cxcl12flox/- and Ocn-Cre:Cxcl12flox/- recipient mice through retro-orbital injection, and the
bone marrow from femurs were harvested and analyzed at 24 hours after injection. C&D. The
numbers of GFP+ mature naive B cells in the bone marrow (C) and spleen (D) were quantified
using flow cytometry. Sample size, n = 11-16 mice per group in all experiments. Data represent
the mean ±SEM, *P < 0.05, compared to Cxcl12flox/- control mice unless otherwise indicated.
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Figure 3.4. Ablation of CXCL12 in Ocn-Cre targeted stromal cells had no effects on plasma
cells (PCs) and primary immune response. A&B. The number of IgM+ PCs (A) and IgG+ PCs
(B) were quantified by flow cytometry in Ocn-Cre:Cxcl12flox/flox and Cxcl12flox/flox mice (n = 6
mice per cohert). C. Ocn-Cre:Cxcl12flox/flox and Cxcl12flox/flox mice were immunized with NPCGG and the amount of NP-specific IgM antibodies were quantified at different time points (n =
5 mice per cohert). Data represent the mean ±SEM.
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Figure 3.5. Ablation of CXCL12 in Ocn-Cre targeted stromal cells reduces the

number of memory B cells in the bone marrow. Ocn-Cre:Cxcl12flox/flox and Cxcl12flox/flox
mice were immunized with NP-CGG. A&B. Two months later, Np-specific IgM- IgDconventional memory B cells were quantified in the bone marrow (A) and the spleen (B) of these
mice by flow cytometry. C&D. Np-specific IgM+ IgD+ memory-like B cells were quantified in
the bone marrow (C) and the spleen (D) of the same mice (n = 6 or 8 mice per cohert). Wildtype
mice were immunized with NP-CGG. Two months later, unenriched cells, IgM+ and IgD+
enriched cells, and IgM- IgD- enriched cells were collected from both the bone marrow and the
spleen of these mice. All of these cells were separately transferred into IgHa/J recipient mice
through retro-orbital injection, followed by secondary NP-CGG immunization one day after
transplant. E. The amount of NP-specific IgG1b in blood serum was quantified one week later
using ELISA, which was represented by light absorbance. Data represent the mean ±SEM, **P
< 0.01; ***P < 0.001, compared to Cxcl12flox/flox control mice unless otherwise indicated.
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CHAPTER 4: CLASSICAL DENDRITIC CELLS IN BONE MARROW
REGULATE HEMATOPOIETIC STEM AND PROGENITOR CELL
TRAFFICKING THROUGH CXCR2 SIGNALING IN SINUSOIDAL
ENDOTHELIAL CELLS

4.1. Introduction
A resident population of classical dendritic cells (cDCs) has been identified in murine bone
marrow, but its contribution to the regulation of hematopoiesis and establishment of the stem cell
niche is largely unknown49. Here, we show that murine bone marrow cDCs are perivascular and
have a cDC2-like immunophenotype. A similar population of cDCs is present in human bone
marrow. RNA expression analysis of sorted BM cDCs showed that expression of many
chemokines and chemokines receptors is distinct from that observed in splenic cDC2s,
suggesting that BM cDCs may represent a unique DC population. Ablation of cDCs results in
hematopoietic stem/progenitor cell (HSPC) mobilization that is greater than that seen with
ablation of bone marrow macrophages. Ablation of cDCs is associated with an expansion of
bone marrow endothelial cells and increased vascular permeability. CXCR2 expression in
sinusoidal endothelial cells and the expression of two CXCR2 ligands, CXCL1 and CXCL2, in
the bone marrow are markedly increased following BM cDC ablation. Treatment of endothelial
cells in vitro with CXCL1 induced increased permeability and transmigration of HSPCs.
Finally, we show that HSPC mobilization after BM cDC ablation is attenuated in mice lacking
CXCR2 expression. Collectively, these data suggest that BM cDCs play an important role in
regulating HSPC trafficking, at least in part, through its regulation of sinusoidal CXCR2
signaling and vascular permeability.
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4.2. Material and Methods
4.2.1. Mouse strains
The CX3CR1gfp/+ mice were a gift from D. Littmann267 (New York University School of
Medicine). Zbtb46dtr (B6(Cg)-Zbtb46tm1(HBEGF)Mnz/J), Zbtb46gfp (129S-Zbtb46tm1Kmm/J), Col2.3GFP (B6.Cg-Tg(Col1a1*2.3-GFP)1Rowe/J) and CXCR2-/- (C.129S2(B6)-Cxcr2 tm1Mwm/J)
mice were obtained from The Jackson Laboratory. CD169dtr mice were a gift from Y.
Obata268,269 (Riken BioResource Center, Ibaraki, Japan). CD169dtr mice were bred with Zbtb46dtr
mice to generate CD169 dtr:Zbtb46dtr mice. Sex- and age-matched mice were used in all
experiments. All mice were inbred on a C57BL/6 background except Zbtb46gfp mice, which
were on a mixed C57BL/6 and 129 SvEv background. The numbers of animals used per
experiment are stated in the figure legends. Mice were maintained under SPF conditions, and all
experimental procedures were performed according to methods approved by the Animal Studies
Committee at Washington University.

4.2.2. Generation of bone marrow chimeras
Six to eight weeks old wild-type Ly5.1/Ly5.2 recipient mice were irradiated with two 550
cGy doses, 6 hours apart. Two million donor bone marrow cells were then injected retroorbitally. Mice were placed on prophylactic antibiotics (trimethoprim-sulfamethoxazole) for 2
weeks following the first dose of irradiation. Mice were analyzed eight weeks after
transplantation.
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4.2.3. Diphtheria toxin administration
Diphtheria toxin (D0564, Sigma) was diluted in PBS containing 0.1% low-endotoxin
bovine serum albumin and administered intraperitoneally at a dose of 200 ng/day for up to 6
days.

4.2.4. CFU-C assays
Cells obtained from the bone marrow, peripheral blood, and spleen were analyzed using a
Hemavet (Drew Scientific) automated cell counter. 40 μL of peripheral blood, 2.5 × 104 bone
marrow cells, or 1.0 × 105 splenic cells were plated in 3mL Mouse Methylcellulose Complete
Media (HSC007, R&D Systems). Cultures were plated in duplicate in 60 mm petri dishes and
incubated in a humidified chamber with 5% CO2 at 37°C. The number of colonies per dish was
counted on day 7.

4.2.5. Flow cytometry
Bone marrow, spleen and peripheral blood were processed for flow cytometry as previously
described270. Cells were analyzed on a Gallios flow cytometer (Beckman Coulter) or sorted on a
Sony SY3200 “Synergy” high-speed cell sorter (Sony). Data analysis was done using FloJo
version 10.0.7 software (TreeStar). The following antibodies were used for staining murine cells:
Gr-1 (RB6-8C5), CD19 (1D3), CD48 (BCM1), B220 (RA3-6B2), CD3e (17A2), Ter119 (TER119), Sca-1 (D7), CD117 (2B8), CD115 (AFS98), CD45 (30-F11), CD45.1 (A20) and CD45.2
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(104) from eBiosciences; CD31 (390), F4/80 (BM8), I-A/I-E (M5/114.15.2), CD11c (N418),
CD150 (TC15-12F12.2), CD169 (3D6.112), CD11b (M1/70) and XCR1 (ZET) from BioLegend.
For cell sorting, classical dendritic cells from bone marrow and spleen were both identified
as CX3CR1-GFPhigh B220- Gr-1- MHCIIhigh CD11chigh F4/80+ cells. Endothelial cells were
identified as Lineage- (CD45- Ter119- Gr-1-) CD31+ cells with Sca1+ to mark arteriolar and Sca1to mark sinusoidal endothelial cell.
For staining human bone marrow cells, the following antibodies were used: CD3 (555332),
CD15 (555401), CD19 (555412) and CD11c (B-ly6) from BD Biosciences; CD13 (WM-15),
CD20 (2H7) and CD56 (MEM188) from eBiosciences; CD33 (P67.6), CD1c (L161), CD14
(M5E2), CD141 (M80) and HLA-DR (L243) from BioLegend.

4.2.6. Immunostaining of bone sections
Mouse hindlimbs were processed for immunostaining as previously described19. The
following antibodies were used: chicken anti-GFP (ab13970, Abcam), rat anti-MHCII (107601,
BioLegend), Rat anti-Sca1 (557403, BD Biosciences), goat anti-VECadherin (AF1002, R&D
Systems), and anti-B220 (12-0452-83, EBioscience); AlexaFluor 488 donkey anti-rat IgG
(Invitrogen), AlexaFluor 488 donkey anti-chicken IgG (Jackson Immunoresearch), and biotinconjugated donkey anti-goat IgG (Jackson Immunoresearch]). In some cases, slides were then
incubated with streptavidin-DyLight 649 (Jackson Immunoresearch) for 30 minutes at room
temperature. Finally, slides were mounted with ProLong Gold antifade reagent with DAPI (Life
Technologies). Images were acquired with an LSM 700 microscope (Carl Zeiss), and images
were processed using Volocity software (PerkinElmer).
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4.2.7. Real-time quantitative RT-PCR
Mouse femurs were flushed with 1 mL of TRIzol reagent (Invitrogen), and RNA was
isolated according to the manufacturer’s instructions. Reverse transcription was performed using
iScript™ cDNA Synthesis Kit (Bio-Rad) according to the manufacturer’s instructions.
Quantitative PCR was performed using iTaq™ Universal Probes Supermix (Bio-Rad) on a
StepOne Plus Real-Time PCR System (Applied Biosystems). RNA content was normalized to
mouse β-actin. Primer and probes for mouse β-actin (Mm01324804_m1), CXCL12
(Mm00445553_m1), CXCL1 (Mm04207460_m1), and CXCL2 (Mm00436450_m1) were
ordered from ThermoFisher.

4.2.8. RNA expression profiling
RNA was purified from sorted classical dendritic cells (cDCs) and endothelial cells using
the Qiagen RNeasy Micro Kit (74004, Qiagen). For cDC RNA samples, libraries were generated
using the NuGen Pico SL kit (NuGEN Technologies, San Carlos, CA) and then hybridized to
Affymetrix Mouse Gene 1.0 ST arrays (Affymetrix, Santa Clara, CA). Gene set enrichment was
performed using the GSEA software (Broad Institute). Differences in gene expression were
determined using Significance Analysis of Microarrays (SAM; Stanford University, Stanford,
CA). Expression data has been submitted to Gene Expression Omnibus, record number.

4.2.9. In vitro permeability test and cell migration assay
Human Umbilical Vein Endothelial Cells (HUVECs) (S200-05N, Sigma) were cultured in
Endothelial Cell Growth Medium (211-500, Sigma) at 37ºC, 5% CO2. 2×105 HUVECs were pre77

cultured in the upper chamber of the Boyden Chamber system for 24 hours to form a HUVEC
layer. During the same time, the HUVEC layer was pre-treated with 40ng/ml recombinant
CXCL1 (453-KC-010/CF, Thermo Fisher) or PBS as control.
To test permeability of the HUVEC layer for large molecules, 400µl Endothelial Cell Growth
Medium containing 100µg/ml Evan’s blue was added to the upper chamber of the cell insert with
0.4µm pores in the membrane (141078, Thermo Fisher). 1ml of Hank balanced salt solution
(H6648-500ML, Sigma) was added to the bottom chamber. After 1 hour incubation at 37ºC, 5%
CO2, Evan’s blue in the bottom chamber was measured by light absorbance at 620nm using
Epoch 2 microplate spectrophotometer (Biotek), and the amount of Evan’s blue was calculated
using a standard curve. Amount of Evan’s blue in the CXCL1 treated samples were normalized
to the amount in the PBS treated control samples for comparison.
To test permeability of the HUVEC layer for cell migration, 400µl medium containing ~5×104
human CD34+ cells were added to the upper chamber of the cell insert with 3µm pores in the
membrane (141080, Thermo Fisher). Human CD34+ cells were enriched from primary human
bone marrow donated by healthy donors, using CD34 MicroBead Kit (130-100-453, Miltenyi
Biotec) and autoMACS Pro Separator (Miltenyi Biotec). 1ml of medium containing 100ng/ml
recombinant CXCL12 (578702, BioLegend) was added to the bottom chamber. Meanwhile,
CXCL1 or PBS was added to the appropriate samples to continue the pre-treatment. After 24
hour incubation at 37ºC, 5% CO2, number of cells migrated to the bottom chamber was
quantified and the percentage was calculated.
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4.2.10. Statistical analyses
Statistical significance was determined using Prism software (GraphPad). Unless otherwise
indicated, unpaired t-test or 1/2-way ANOVA analyses were used to evaluate the significance of
differences between two or multiple groups. All data are presented as mean ±SEM.

4.3. Results
4.3.1. Classical dendritic cells (cDCs) are enriched in the perivascular region and may be
functionally specific for the perivascular niche.
Dendritic cells (DCs) are a component of the innate immune system and are distributed
throughout the body. DCs are professional antigen presenting cells that contribute to immune
cell activation through the secretion of cytokines and chemokines. DCs display considerable
phenotypic and functional heterogeneity, suggesting that DCs in specific tissues may have
evolved to perform distinct functions37-39. DCs include classical DCs (cDCs) with dendritic
morphology and outstanding capacity for presenting antigens and priming T cells, and
plasmacytoid DCs (pDCs) which are lymphocyte-like cells specialized in the production of type
I interferons40,41,43. cDCs may be further divided into type 1 cDCs (cDC1s), mainly against
viruses, tumors and intracellular pathogens, and type 2 cDCs (cDC2s), mainly agaisnt parasites,
allergens, extracellular bacteria and fungi42. A prior study identified a resident population of
cDCs in the bone marrow and provided evidence that these cells promote the survival of
circulating mature B cells in the bone marrow49. To better characterize BM cDCs, we developed
a multicolor flow cytometry to analyze myeloid cell populations in Cx3cr1gfp/+ mice, which
express high levels of green fluorescent protein (GFP) in monocytes and BM cDCs, but not in
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bone marrow macrophages7,267. Monocytes were identified as CX3CR1-GFPhigh MHC IIlow
B220-/CD19- cells (Fig. 4.1a), and, consistent with prior studies, expressed F4/80 but were
mostly negative for CD11c and CD169 (Fig. 4.1b)271,272. Bone marrow macrophages were
identified as CX3CR1-GFPlow, MHC II+, B220-/CD19- cells and expressed CD169 and F4/80,
but little CD11c. Finally, BM cDCs were identified as CX3CR1-GFPhigh and MHC IIhigh B220/CD19- cells. As expected, BM cDCs expressed a high level of CD11c and F4/80, but a low
level of CD16951. cDCs represent 0.048 ±.017% of nucleated cells in mouse bone marrow
compared to 0.096 ±.047% for macrophages (n = 11 mice). A prior study showed that BM
cDCs are perivascular, although this study did not distinguish between venous sinusoids and
arterioles49. We show that the great majority of CX3CR1-GFPhigh and MHC IIhigh DCs in the
bone marrow are perivascular (Fig. 4.1c: iv-viii), with the majorit
venous sinusoid or arteriole (Fig. 4.1d, e).
To further characterize mouse BM cDCs, we assessed their expression of XCR1 and CDllb,
which are selectively expressed on cDC1s and cDC2s, respectively42. Nearly all of the cDCs
express CD11b but not XCR1, suggesting that the majority of murine BM DCs are cDC2-like
cells (Fig. 4.1f). We next examined bone marrow from healthy donors to determine whether
cDCs also are present in human bone marrow. Indeed, the percentage of cDCs in human bone
marrow (0.076 ±.041%, n = 3 donors) was similar to that seen in murine bone marrow.
Moreover, the majority of cDCs in human bone marrow express CD1c but not CD141, consistent
with a cDC2-like phenotype (Fig. 4.1g)42. RNA expression profiling was performed on sorted
murine BM cDCs and compared to prior data generated using splenic cDC2 cells. Surprisingly,
the patterns of gene expression for chemokines and chemokine receptors were strikingly
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different, suggesting that BM cDCs may represent a unique dendritic cell population with
distinct functional properties (Fig. 4.1h).

4.3.2. BM cDC ablation induces a loss of macrophage and HSPC mobilization
To assess their functional importance, BM cDCs were ablated using CD11cdtr mice. A prior
study showed that treatment with diphtheria toxin (DT) results in efficient ablation of cDCs in
the bone marrow, but it is also associated with systemic toxicity leading to death273,274. As
reported previously275, to circumvent DT-induced lethality, we transplanted bone marrow from
CD11cdtr mice into irradiated wild-type congenic recipients (Supplemental Fig. 4.1a). Treatment
of CD11cdtr bone marrow chimeras with DT did not affect the number of HSPCs in the bone
marrow (Fig. 2a, Supplemental Fig. 4.1b), but resulted in a modest HSPC mobilization into
spleen and blood (Fig. 2b,c, Supplemental Fig. 4.1c), as quantified by CFU-C and C-kit+ Sca1+
Lin- (KSL) marked HSPCs. Prior studies have shown that CD11cdtr targets certain macrophage
subsets in peripheral organs 274,276,277. Indeed, we observed a loss of bone marrow macrophages
after 6 days treatment of DT (Fig. 4.2d). Of note, after 1 day treatment of DT, cDCs but not
macrophages in the bone marrow were depleted, raising the possibility that macrophage loss is
secondary to cDC loss (Fig. 4.2d).
Recent studies have identified Zbtb46 as a transcription factor that is expressed in cDCs but
not in pDCs, macrophages or other myeloid or lymphoid cells278,279. To confirm the specificity
of Zbtb46 expression in cDCs, we analyzed Zbtb46gfp mice, in which GFP is knocked into the
Zbtb46 locus279. As expected, Zbtb46-GFP was expressed at high levels in BM cDCs, but in
neither bone marrow macrophages nor monocytes (Fig. 4.2e). Since endothelial cells also
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express Zbtb46278,279, we transplanted Zbtb46dtr bone marrow into irradiated wild-type recipients
to restrict Zbtb46dtr to the hematopoietic lineage, thus to assess the effect of BM cDC ablation on
HSPCs. DT treatment on Zbtb46dtr bone marrow chimeras resulted in a marked loss of BM
cDCs (Fig. 4.2f). Similar to CD11cdtr bone marrow chimeras, we also observed a loss of bone
marrow macrophages in the same mice following DT treatment, which occurred later than BM
cDC ablation (Fig. 4.2f). To determine whether this loss of macrophages was cell-autonomous,
we generated mixed wild-type and Zbtb46dtr bone marrow chimeras using similar transplantation
method. As expected, DT treatment resulted in the loss of Zbtb46dtr derived but not wild-type
derived BM cDCs (Fig. 4.2g). In contrast, DT treatment resulted in decreases of both wild-type
and Zbtb46dtr derived bone marrow macrophages (Fig. 4.2h). Collectively, these data strongly
suggest that BM cDC ablation results in a secondary and non-cell autonomous loss of bone
marrow macrophages.
Ablation of bone marrow macrophages has been reported to alter the HSPC niche and induce
HSPC mobilization7,52. Therefore, to precisely assess the role of BM cDCs on HSPC regulation
and maintenance, it was necessary to include additional macrophage ablation model and double
ablation model for comparison with BM cDC ablation model. Recent studies have reported
CD169dtr may ablate bone marrow macrophages specifically7,53,268,269. Thus, we transplanted
Zbtb46dtr, CD169dtr, or CD169dtr: Zbtb46dtr bone marrow into irradiated wild-type recipients. 6
days of DT treatment on all three bone marrow chimeras did not induce any significant changes
in bone marrow and spleen cellularity (Supplemental Fig. 4.1d,e). In the bone marrow, all three
chimeras showed no significant differences of KSL cells or CD150+ CD48- KSL (KSL-SLAM)
marked HSCs (Fig. 4.2i, supplemental Fig. 4.1f), although mild increases of CFU-C were
observed (Fig. 4.2l). Ablation of bone marrow macrophages in CD169dtr bone marrow chimeras
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resulted in weak mobilization of KSL cells and CFU-C into spleen and blood, but there was little
mobilization of KSL-SLAM cells into spleen (Fig. 4.2j,m). In contrast, ablation of BM cDCs in
both Zbtb46dtr and CD169dtr: Zbtb46dtr bone marrow chimeras resulted in stronger mobilizations
of KSL cells, KSL-SLAM cells and CFU-C into spleen and blood (Fig. 4.2j,k,m,n).
Interestingly, there were no significant differences of HSPC mobilizations between Zbtb46dtr and
CD169dtr: Zbtb46dtr bone marrow chimeras (Fig. 4.2j,k,m,n). Overall, these data demonstrate
that ablation of bone marrow macrophages only induces weak HSPC mobilization in bone
marrow chimeras, and ablation of BM cDCs may induce stronger HSPC mobilization through
both macrophage dependent and independent pathways.

4.3.3. BM cDC ablation affects bone marrow vascular endothelial cells
Given BM cDCs are enriched in the perivascular region, we next assessed bone marrow
vascular permeability after BM cDC ablation, as it has been reported to positively affect cell
mobilization in bone marrow280,281. BSA-FITC was injected into Zbtb46dtr bone marrow
chimeras treated with PBS, 1 day of DT, or 6 days of DT. Mice were harvested 15 minutes later
and immunofluorescent (IF) staining was performed on femurs to quantify BSA-FITC for
estimating bone marrow vascular permeability (Fig. 4.3a)282. We observed a trend of increasing
vascular permeability along BM cDC ablation (Fig. 4.3c). In addition, we quantified the
percentage of vascular endothelial cells (VECs) in whole bone marrow in the same Zbtb46dtr
bone marrow chimeras by IF staining and found the percentage of VECs increased after BM
cDC ablation (Fig. 4.3b,d). Flow cytometry further confirmed that the number of bone marrow
VECs increased 1 day after BM cDC ablation (Fig. 4.3e). Collectively, these data show that
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ablation of BM cDCs may result in potential activation of bone marrow VECs for increased
vascular permeability and angiogenesis.

4.3.4. BM cDC ablation activates sinusoidal endothelial cells and sinusoidal CXCR2
signaling
To determine potential molecular pathways involved in BM cDC ablation induced
activation of bone marrow VECs, we performed gene expression analysis in endothelial cells
from Zbtb46dtr bone marrow chimeras treated with 1 day of DT or PBS. At this time point, only
BM cDCs were ablated, but not bone marrow macrophages, thus the result would be specific to
BM cDC ablation. Sinusoidal endothelial cells (SECs) were marked as Lin- CD31+ Sca1- cells
and arteriolar endothelial cells (AECs) were marked as Lin- CD31+ Sca1+ cells, and both
populations were sorted using FACS. We performed RNA microarray analysis on both
populations, and PCA was performed to measure and visualize differences for each population
before or after BM cDC ablation. While AECs showed no significant differences between the
two conditions, SECs may be activated after BM cDC ablation for differential gene expressions
(Supplemental Fig. 4.2a,b). To further test this possibility, we performed RNA sequencing
analysis in SECs from Zbtb46dtr bone marrow chimeras treated with 1 day of DT or PBS. We
performed t-distributed stochastic neighbor embedding (t-SNE) to measure and visualize
differences between the two conditions and the result was consistent with the microarray analysis
(Fig. 4.4a). SECs were activated after BM cDC ablation and there were 635 significantly
differentially expressed genes with >5 fold differences, p-value < 0.05 and FDR < 0.02. To
search for potential pathways activated in SECs after BM cDC ablation, gene set enrichment
analysis (GSEA) was performed. The most enriched gene set showed activation of chemokines
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and cytokines related pathways (Fig. 4.4b). Also, gene set for angiogenesis was highly enriched,
which was consistent with the observed expansion of VECs measured by IF staining and flow
cytometry (Fig. 4.3d,e and Fig. 4.4c). Among expressed chemokine receptors in SECs, CXCR2
was most highly up-regulated after BM cDC ablation (Fig. 4.4d). Importantly, recent and early
studies have reported CXCR2 activation could induce vascular permeability and HSPC
mobilization72,283-285. We performed quantitative real-time PCR (qRT-PCR) on whole bone
marrow RNAs from Zbtb46dtr bone marrow chimeras treated with PBS, 1 day or 6 days of DT.
Both ligands for CXCR2, CXCL1 (KC) and CXCL2 (Gro-β) were up-regulated following BM
cDC ablation (Fig. 4.4e,f). To confirm that this observation was not due to a non-specific upregulation of chemokines induced by acute inflammation, we measured whole bone marrow
RNA level of CXCL12, a common and pro-inflammatory chemokine in the bone marrow, and
found no increase after BM cDC ablation (Supplemental Fig. 4.2c). To further test whether there
was an acute inflammation, we measured neutrophil numbers in blood and bone marrow286,287,
and found little or no increase (Supplemental Fig. 4.2d,e). Both results suggested up-regulations
of CXCL1 and CXCL2 were specific to BM cDC ablation. Thus, CXCR2 is activated in SECs
after BM cDC ablation, which may play an important role for regulating sinusoidal vascular
permeability and HSPC mobilization.

4.3.5. CXCR2 signaling pathway is important for BM cDC ablation induced HSPC
mobilization
To test our hypothesis on the role of CXCR2, we first confirmed prior studies11-13, 32 by
testing whether activation of CXCR2 may induce vascular permeability using in vitro migration
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assay. Human umbilical vein endothelial cells (HUVECs) were plated in the upper chamber of
the Boyden chamber for migration assay to form a HUVEC layer, and treated with PBS or
recombinant CXCL1 (rCXCL1) to activate CXCR2 signaling (Fig. 4.5a). To test vascular
permeability of the HUVEC layer for large molecules, Evan’s blue was added to the upper
chamber of the Boyden chamber with 0.4μm pores in the membrane (Fig. 4.5a). Quantified by
light absorbance, the amount of Evan’s blue in the bottom chamber after 1 hour increased
modestly upon CXCR2 activation, suggesting an increased permeability of the HUVEC layer
(Fig. 4.5b). To test the effects of CXCR2 activation on HSPC migration, CD34+ cells were
isolated from healthy human bone marrow and added to the upper chamber of the Boyden
chamber with 3μm pores in the membrane, and medium containing recombinant CXCL12 was
added to the bottom chamber to induce cell migration288-290 (Fig. 4.5a). A modest increase of
cell migration through the HUVEC layer was observed after 24 hours upon CXCR2 activation
(Fig. 4.5c). To test the role of CXCR2 signaling on BM cDC ablation induced HSPC
mobilization, we transplanted Zbtb46dtr bone marrow into irradiated Cxcr2-/- recipients,
restricting knock-out of CXCR2 to the stromal cells and endothelial cells in the bone marrow of
these recipients. We then compared them with previous Zbtb46dtr bone marrow chimeras in
wild-type recipients, for HSPC mobilization after 6 days treatment of PBS or DT (Fig. 4.5d).
BM cDC ablation did not affect bone marrow and spleen cellularity in Zbtb46dtr Cxcr2-/- bone
marrow chimeras, and there was a mild decrease of cellularity compared to Zbtb46dtr wild-type
bone marrow chimeras with the same treatment (Supplemental Fig. 4.3a,b). In the bone marrow
of Zbtb46dtr Cxcr2-/- bone marrow chimeras, BM cDC ablation did not induce any significant
differences in KSL cells (Fig. 4.3e) and KSL-SLAM cells (Supplemental Fig. 4.3c), although
there might be a trend of mild increase of CFU-C which was similar to the pattern observed in
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Zbtb46dtr wild-type bone marrow chimeras (Supplemental Fig. 4.3d). In the spleen of Zbtb46dtr
Cxcr2-/- bone marrow chimeras, BM cDC ablation resulted in weaker mobilizations of KSL cells,
KSL-SLAM cells and CFU-C, compared to Zbtb46dtr wild-type bone marrow chimeras (Fig.
4.5f-h). Similar to the spleen, a weaker mobilization of CFU-C was observed in the blood of
Zbtb46dtr Cxcr2-/- bone marrow chimeras, compared to Zbtb46dtr wild-type bone marrow
chimeras (Fig. 4.5i). Collectively, data from both in vitro and in vivo experiments support our
hypothesis that CXCR2 signaling plays an important role in the regulation of HSPC mobilization
induced after BM cDC ablation.

4.4. Summary
In conclusion, data from this study suggests BM cDC as a novel perivascular niche
component that regulates HSPC retention and trafficking, at least in part, through its regulation
of sinusoidal CXCR2 signaling and vascular permeability. This observation is consistent with
the findings from our colleagues, where Dr. John Dipersio’s group shows endothelial CXCR2 is
important for Gro-β induced neutrophil mobilization into the blood. Our results do not provide
evidence to explain how BM cDCs regulate SECs. However, as bone marrow macrophage has
been reported to regulate HSPCs through indirect regulation of stromal cells7,52, we suspect
similar process may be involved.
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4.7. Figures
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Figure 4.1. Classical dendritic cells (cDCs) are enriched in the perivascular region and may
be functionally specific for the perivascular niche. (a) Representative flow plots showing the
gating strategy used to identify bone marrow monocytes, macrophages, and cDCs in Cx3cr1gfp/+
mice. Gr-1hi neutrophils and B220+/CD19+ B cells were excluded as shown in the left panel.
Monocytes were identified as CX3CR1-GFP+ MHC IIlow cells, cDCs as CX3CR1-GFPhigh
MHCIIhigh cells, and macrophages as CX3CR1-GFPlow MHCII+ B220- cells. (b) The gated
monocyte, macrophage, and cDC populations were profiled for expression of the indicated
lineage markers. FMO, fluorescence minus one control. (c) Representative photomicrographs of
femur sections from Cx3Cr1gfp/+ mice. Slides were stained with GFP (green) (i), MHC II (red)
(ii) and the merge (iii). Slides were stained with GFP (green) (iv), Sca1+ arterioles (red) (v), VECadherin+ venous sinusoids and arterioles (white) (vi) and merge (vii); higher magnification of
boxed region (viii). Yellow arrows indicate cDCs. Counterstaining with DAPI highlights nuclei
(blue). (d,e) Quantification of the distance from cDCs to the nearest venous sinusoid (d) or
arteriole (e) (data pooled from n = 3 mice). (f) Representative flow plot showing the expression
of two murine cDC markers, XCR1 for cDC1 and CD11b for cDC2, in murine bone marrow
cDCs, gated as Gr-1- B220- MHCIIhigh CD11chigh cells. (g) Representative flow plot showing the
expression of two human cDC markers, CD141 for cDC1 and CD1c for cDC2, in human bone
marrow cDCs, gated as Lin- CD14- CD13+ CD33+ CD11c+ HLA-DR+ cells. (h) A heat map
comparing the expressions of all chemokines and their receptors between mouse BM cDCs and
mouse spleen (Sp) cDC2s (GSE110789, Durai V. 2018). Data represent mean ±SEM.
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Figure 4.2. BM cDC ablation induces a loss of macrophage and HSPC mobilization. (a-d)
Bone marrow from CD11cdtr mice were transplanted into irradiated wildtype recipients and after
eight weeks, the resulting chimeras were treated with PBS or DT for 6 days. The number of
CFU-C in bone marrow (a), spleen (b) and blood (c) were quantified (n = 10 mice per cohert).
(d) CD11cdtr bone marrow chimeras were treated with DT for 1 day (n = 3 mice), 6 days (n = 10
mice), or with PBS (n = 10 mice), and BM cDCs and macrophages were quantified by flow
cytometry. (e) Bone marrow monocytes (Gr-1low B220- CD115+ cells), macrophages (B220MHCII+ F4/80+ cells), and cDCs (MHCIIhigh CD11chigh cells) from Zbtb46gfp/+ mice were
assessed for Zbtb46-GFP expression. FMO means fluorescence minus one control. (f) Zbtb46dtr
bone marrow chimeras were generated using same method and were treated with DT for 1 day (n
= 5 mice), 2 days (n = 5 mice), 6 days (n=12 mice) or with PBS (n = 11mice) and BM cDCs and
macrophages were quantified. (g,h) Bone marrow from wild-type (Ly5.1) and Zbtb46dtr (Ly5.2)
mice were mixed (1:1) and transplanted into irradiated wild-type recipients (Ly5.1/5.2). The
resulting wild-type and Zbtb46dtr mixed bone marrow chimeras were treated with PBS or DT for
6 days, and the number of cDCs (g) and macrophages (h) in the bone marrow that were derived
from wild-type (WT) or Zbtb46dtr (Zbtb46-DTR) cells were quantified (n = 5 mice per cohort).
(i-n) Zbtb46dtr (Zbtb46-DTR), CD169dtr (CD169-DTR) and CD169 dtr:Zbtb46dtr (CD169/Zbtb46DTR) bone marrow were transplanted into wild-type recipients. Eight weeks after
transplantation, these mice were treated with PBS or DT for 6 days. The numbers of Lineage(CD45, CD31, Ter119, Gr-1) Sca1+ C-kit+ (KSL) cells in bone marrow (i) and spleen (j), the
number of CD150+ CD48- KSL (KSL-SLAM) cells in spleen (k), and the numbers of CFU-C in
bone marrow (l), spleen (m) and blood (n) were quantified (n = 8-18 mice per cohort). Data
represent the mean ±SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 compared
with PBS-treated or day 0 mice if no top line indicating the specific comparison groups. “n.s.”
means no significance.
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Figure 4.3. Ablation of BM cDCs affects bone marrow vascular endothelial cells (VECs).
(a,b) Representative photomicrographs of femur sections from Zbtb46dtr bone marrow chimeras
treated with PBS (left), 1 day of DT (1D-DT, middle) or 6 days of DT (6D-DT, right). (a) BSAFTIC was injected into these mice 15mins before sacrifice, and was labeled in green. Slides were
stained for VE-Cadherin+ /CD31+ VECs (red). (b) Slides were stained for VE-Cadherin+ /CD31+
VECs (red). Counterstaining with DAPI highlights nuclei (blue). Original magnification, 200X.
(c) Vascular permeability in bone marrow for BSA-FITC was measured and normalized to PBS
treated group. (d) Percentage of VEC volumes in the bone marrow of these mice were quantified
(n = 9, 8, 7 mice for PBS, 1D-DT and 6D-DT groups). (e) Bone marrow VECs in Zbtb46dtr bone
marrow chimeras treated with PBS or 1D-DT were quantified by flow cytometry, gated as
Lineage- (CD45, Ter119, Gr-1) CD31+ cells (n = 4 or 6 mice for PBS or 1D-DT groups). Data
represent the mean ±SEM. *P < 0.05; **P < 0.01compared with PBS-treated mice.
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Figure 4.4. Ablation of BM cDCs activates sinusoidal endothelial cells and sinusoidal
CXCR2 signaling. (a) Sinusoidal endothelial cells were sorted from Zbtb46dtr bone marrow
chimeras treated with PBS or 1D-DT, and RNA-sequencing (RNA-seq) analysis was performed
in these cells. We performed t-distributed stochastic neighbor embedding (t-SNE) test to measure
and visualize differences between PBS (n = 4 mice) and 1D-DT (n = 3 mice) groups. (b,c) RNAseq data were analyzed using gene set enrichment analysis (GSEA) and two significantly
enriched gene sets of interest were shown. (d) Expression levels of all expressed chemokine in
sinusoidal endothelial cells. (e) CXCL1 and (f) CXCL2 expressions were analyzed by
quantitative real-time PCR (qRT-PCR) in whole bone marrow from Zbtb46dtr bone marrow
chimeras treated with PBS, 1D-DT or 6D-DT (n = 6, 5, 5 mice for these groups). Data represent
the mean ±SEM. *P < 0.05; **P < 0.01; ***P < 0.001compared with PBS-treated mice.
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Figure 4.5. CXCR2 signaling pathway is important for BM cDC ablation induced HSPC
mobilization. (a-c) Human umbilical vein endothelial cells (HUVECs) were cultured in
endothelial cell (EC) medium in the upper chamber of the Boyden Chamber for migration assay.
HUVECs were treated with PBS or recombinant CXCL1, incubated at 37ºC, 5% CO2. (b)
Evan’s blue was added to the upper chamber with Hank’s balanced salt saline (HBSS) in the
bottom chamber, polycarbonate membrane pore size = 0.4µm. After 1 hour incubation, the
amount of Evan’s blue in the bottom chamber was quantified by measuring light absorbance (n =
5 or 6 per group). (c) CD34+ human bone marrow cells from healthy donor were added to the
upper chamber, with EC medium containing 100ng/mL SDF1in the bottom chamber,
polycarbonate membrane pore size = 3µm. After 24 hours incubation, the number of migrated
CD34+ cells in the bottom chamber was quantified by cellometer (n = 11 or 12 per group). (d)
Bone marrow cells from Zbtb46dtr mice were transplanted into irradiated wild-type (previously
done in Fig 2) or Cxcr2-/- recipients. Eight weeks after transplantation, mice were treated with
PBS or DT for 6 days. (e-i) The number of KSL cells in bone marrow (e) and spleen (f), the
number of KSL-SLAM cells in spleen (g), and the number of CFU-C in spleen (h) and blood (i)
were quantified (n = 12, 16, 6, 6 mice for WT PBS, WT DT, Cxcr2-/- PBS and Cxcr2-/- DT
groups). Data represent the mean ±SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001
comparing to PBS-treated group if no top line indicating the specific comparing groups.
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4.8. Supplemental Figures

Supplemental Figure 4.1. BM cDC ablation induces a loss of macrophage and HSPC
mobilization. (a) Bone marrow from CD11cdtr mice were transplanted into irradiated wild-type
recipients and after eight weeks, the resulting chimeras were treated with PBS or DT for 6 days.
(b,c) KSL cells were quantified in bone marrow (b) and spleen (c) (n = 8-10 mice per cohert).
(d-f) Zbtb46dtr (Zbtb46-DTR), CD169dtr (CD169-DTR) and CD169 dtr:Zbtb46dtr (CD169/Zbtb46DTR) bone marrow were transplanted into wild-type recipients. Eight weeks after
transplantation, mice were treated with PBS or DT for 6 days. Total cellularity in bone marrow
(d) and spleen (e), and KSL-SLAM cells (f) in bone marrow were quantified (n = 10-18 mice per
cohort). Data represent the mean ±SEM. *P < 0.05; **P < 0.01 compared with PBS-treated
mice.
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Supplemental Figure 4.2. Ablation of BM cDCs activated sinusoidal endothelial cells and
sinusoidal CXCR2 signaling. (a,b) Arteriolar and sinusoidal endothelial cells (AECs and SECs)
were sorted from Zbtb46dtr bone marrow chimeras treated with PBS or 1 day of DT (1D-DT),
and RNA microarray analyses were performed in these populations. We performed principal
component analysis (PCA) to measure and visualize differences between PBS and 1D-DT
groups, for (a) AECs (n = 4 or 5 mice for PBS or 1D-DT groups) and (b) SECs (n = 2 or 3 mice
for PBS or 1D-DT groups). (c) CXCL12 expression was measured by quantitative real-time
PCR (qRT-PCR) in whole bone marrow from Zbtb46dtr bone marrow chimeras treated with PBS,
1D-DT or 6D-DT (n = 6, 5, 5 mice for these groups). (d,e) Zbtb46dtr bone marrow chimeras were
treated with PBS or 1 day of DT, neutrophils were quantified in blood by Hemavet Hematology
Analyzer (n = 11 or 4 for each group) (d) and in bone marrow by flow cytometry, gated as Gr1high cells (n = 11 mice per group) (e). Data represent the mean ±SEM *P < 0.05 compared
with PBS-treated mice.
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Supplemental Figure 4.3. CXCR2 signaling pathway is important for BM cDC ablation
induced HSPC mobilization. (a-d) Bone marrow cells from Zbtb46dtr mice were transplanted
into irradiated wild-type (previously done in Fig 2) or Cxcr2-/- recipients. Eight weeks after
transplantation, mice were treated with PBS or DT for 6 days. Total cellularity in bone marrow
(a) and spleen (b), KSL-SLAM cells (c) and CFU-C (d) in bone marrow were quantified (n = 617 mice per cohort). Data represent the mean ±SEM. *P < 0.05.
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CHAPTER 5: SUMMARY AND FUTURE DIRECTIONS

The goal of this work is to improve the overall understanding of the bone marrow
perivascular niche. Here, we further characterized a known bone marrow niche component,
mesenchymal stromal cells, and proposed a novel niche cell component, bone marrow classical
dendritic cells (BM cDCs). In Chapter 2, we examined the heterogeneity of mesenchymal
stromal cells using different transgenic Cre models and identified a subset of CAR cells
potentially enriched for osteoprogenitors. This study further highlights the heterogeneity of
mesenchymal stromal cells in the bone marrow and suggests appropriate models to interrogate
this heterogeneity. In Chapter 3, we used a Cxcl12 conditional deletion model and multiple
stromal specific transgenic Cre models to assess the role of CXCL12 from different stromal cell
populations on the regulation of B lymphopoiesis. We show that CXCL12 from Ocn-Cre
targeted stromal cells is important in the regulation of mature naive B cells and memory B cells
in the bone marrow. This study demonstrates the functional heterogeneity of stromal cells and
may provide insights to the development of potential therapies for B cell related diseases. In
Chapter 4, we used ablation models to assess the role of BM cDCs in the regulation of HSPCs in
the bone marrow and discovered that BM cDCs serve as an important hematopoietic niche
component to regulate HSPC trafficking through its regulation of sinusoidal CXCR2 signaling.
These data improve our understanding of the hematopoietic niche and provide potential targets
for the development of cell mobilization related treatment.
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5.1. Targeting mesenchymal stromal cells with different Cre-recombinase transgenes
5.1.1. Summary
In Chapter 2, we characterized three Cre-recombinase transgenes for their targeting
specificity on bone marrow stromal cells. Ocn-Cre has been widely used to target osteoblasts in
past studies245,247,248. Our data show that Ocn-Cre targets not only all osteoblasts, but also
osteocytes, ~70% of CAR cells, and the majority of arteriolar pericytes. Dmp1-Cre has been
widely used to target osteocytes 250,252,266. We show that Dmp1-Cre targets all osteoblasts, as
well as ~30% of CAR cells. Expression profiling of these CAR cells shows higher expression of
genes associated with mature osteoblasts, suggesting their potential enrichment for
osteoprogenitors. We also, for the first time, characterized the bone marrow stromal cells
targeted by a Tagln-Cre transgene, and show that Tagln-Cre targets all osteoblasts, ~70% of
CAR cells, and both venous sinusoidal and arteriolar pericytes. Collectively, we have rigorously
defined the targeting specificities in the bone marrow for the three Cre-recombinase transgenes.
Ocn-Cre and Dmp1-Cre target broader stromal cell populations than previously appreciated,
which should be considered when designing future studies. Moreover, we present Tagln-Cre as a
new tool to efficiently target both venous sinusoidal and arteriolar pericytes in the bone marrow.

5.1.2. Are Dmp1-Cre targeted stromal cells truly enriched for osteoprogenitors?
Our data suggests that Dmp1-Cre targeted stromal cells may be enriched for
osteoprogenitors. However, this hypothesis is only based on gene expression profiling using
RNA microarray and further experiments are required to confirm this finding. First, quantitative
real-time PCR may be used to confirm the up-regulation of genes associated with mature
osteoblasts, which were detected by RNA microarray. Second, we may perform functional
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assays to test the osteoprogenic capacity of Dmp1-Cre targeted stromal cells. We may sort these
cells using the same strategy as for gene expression profiling, and culture the sorted cells in vitro
to test their multi-lineage capacity using colony forming unit (CFU) assays for adipocytes (CFUA), osteoblasts (CFU-Ob) and chondrocytes (CFU-Ch). Total CAR cells and Ocn-Cre targeted
CAR cells may also be sorted and cultured to test their multi-lineage capacity. By comparing
their multi-lineage capacities, especially the capacity to form osteoblasts among these different
subsets of CAR cells, we will be able to confirm whether Dmp1-Cre targeted stromal cells are
truly enriched for osteoprogenitors.

5.1.3. Further characterize the heterogeneity of CAR cells
Prior studies have discussed the heterogeneity of mesenchymal stromal cells in the bone
marrow and have described different subsets of stromal cells for their specific functions, such as
LepR+ cells and Nestin-GFP cells10,12. In this study, we further identified Dmp1-Cre targeted
stromal cells to include potential osteoprogenitors. However, it remains unanswered how many
functionally different subsets of stromal cells may exist. Recent studies suggest that distinct
niches may exist to regulate different types of cells, such as quiescent or more proliferative
HSCs12,18,79. Further dissecting the heterogeneity of stromal cells will provide insights to better
characterize distinct niches with more specific functions. This will improve our understanding of
the regulation of different cells in the bone marrow, providing fundamental knowledge to support
future research in both basic and clinical science. For future studies, CAR cells, representing the
majority of mesenchymal stromal cells, may be sorted from Cxcl12gfp mice and analyzed by
single cell RNA sequencing. Based on the gene expression profile, clustering analysis may be
performed to discover more specific subsets of CAR cells. It is important to notice that due to the
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overall similarity among CAR cells, clustering analysis may be inefficient to detect more specific
cell subsets. Alternatively, differential gene expressions should also be analyzed and such
analysis should focus on genes representing surface markers or genes with important functions in
the regulation of the bone marrow niche.

5.2. CXCL12 from Ocn-Cre targeted mesenchymal stromal cells regulates late-stage
B cell development
5.2.1. Summary
In Chapter 3, we assessed the role of CXCL12 from different stromal cells in the regulation
of B cell development in the bone marrow. We show that CXCL12 from Ocn-Cre targeted
stromal cells is specifically important for the homing and/or retention of mature naive B cells.
We also show that Dmp1-Cre targeted stromal cells play no significant role in the regulation of B
cell development, consistent with our prior study showing that Dmp1-Cre targeted CAR cells
express low levels of IL-719. In addition, our data suggests that CXCL12 from Ocn-Cre targeted
stromal cells regulates memory B cells specifically in the bone marrow. Collectively, these data
suggest that B cells require distinct niches at different stages of development, and Ocn-Cre
targeted stromal cells may represent a specific niche for late-stage B cell development.
Moreover, Ocn-Cre targeted stromal cells may also regulate memory B cells, thus potentially
contributing to the regulation of B cell immune memory and humoral immunity. This study may
provide insights to further understand immune memory, which in turn will contribute to
improvements in the treatment of the relevant diseases.
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5.2.2. Functionally characterize the role of bone marrow memory B cells in the regulation
of humoral immunity
In this study, we used NP-CGG to induce NP-specific memory B cells and observed a
significant reduction of these cells in the bone marrow of Ocn-Cre:Cxcl12flox/flox mice compared
to the Cxcl12flox/flox control mice. Of notice, the number of memory B cells in the bone marrow
constitutes ~40% of total memory B cells, including memory B cells from the spleen (Fig
3.5A&B), assuming one femur represents ~9% of total bone marrow cells. We observed ~50%
reduction in memory B cells in the bone marrow of Ocn-Cre:Cxcl12flox/flox mice, roughly
representing a 20% reduction in total memory B cells. It remains questionable whether this
modest reduction of memory B cells has a significant impact on memory B cell derived humoral
immunity. To test this, we have an ongoing study in which a similar number of bone marrow
cells containing NP-specific memory B cells from Ocn-Cre:Cxcl12flox/flox or Cxcl12flox/flox mice
will be transferred into IgHa/J mice, followed by secondary immunization with NP-CGG.
ELISA will be performed to quantify the NP-specific IgG1b antibodies generated by NP-specific
memory B cells from the donor mice. In addition, using the same method, we could compare the
function of NP-specific memory B cells from the bone marrow and the spleen.

5.2.3. How does CXCL12 ablation in Ocn-Cre targeted stromal cells affect other cells in the
bone marrow?
Our study focused on how CXCL12 ablation in different stromal cells regulates B cell
development. However, our preliminary data also suggests a significant reduction of T cells,
especially CD8+ T cells and Foxp3+ regulatory T (Treg) cells in the bone marrow upon CXCL12
ablation in Ocn-Cre targeted stromal cells (Fig 5.1A). In contrast, no significant reduction of T
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cells was observed in Dmp1-Cre:Cxcl12flox/flox mice (Fig 5.1B). These data suggest that CD8+ T
cells and Treg cells, as well as mature naive B cells and memory B cells, may share the same
niche in the bone marrow. A recent study has suggested Foxp3+ regulatory T cells play an
important role in the regulation of B lymphopoiesis291. Thus, it is possible that Treg cells may be
important for the regulation of mature naive B cells and memory B cells in our CXCL12 ablation
model. To test this possibility, the same CXCL12 ablation model may be applied in a
background of Treg cell deficient mice. The effects of CXCL12 ablation in Ocn-Cre targeted
stromal cells on mature naive B cells and memory B cells will be assessed in the lack of Treg
cells.
Moreover, prior studies have suggested CD8+ T cells in the bone marrow may function as
memory T cells292. Although this hypothesis needs further confirmation, it is important to note
that two potential populations of memory B cells and memory T cells are both regulated by
CXCL12 from Ocn-Cre targeted stromal cells. These data indicate that a unique bone marrow
niche may exist to regulate memory cells, thus potentially regulating immune memory in the
bone marrow. More interestingly, the fact that memory B cells and memory T cells may share
the same niche suggests the potential necessity in our future research to focus on a whole system,
instead of a specific cell type. This may provide a different perspective to investigators when
considering and designing their future experiments.

5.2.4. Do Ocn-Cre targeted stromal cells regulate mature naive B cells and memory B cells
through other pathways?
CXCL12 is an important bone marrow niche factor regulating hematopoiesis and B
lymphopoiesis20. Our prior study has suggested the critical role of CXCL12 in the regulation of
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B cell development at different stages3. In this study, we show that CXCL12 from Ocn-Cre
targeted stromal cells regulates mature naive B cells and memory B cells, suggesting these cells
are potentially an important component for a specific B cell niche. As previously discussed, B
cell development is a complicated process requiring the contribution from different molecular
pathways. To better understand the role of Ocn-Cre targeted stromal cells in the regulation of B
lymphopoiesis, it is necessary to further characterize these cells to test whether additional
pathways are involved in their regulation of B cells.
To assess this possibility, we are currently breeding Ocn-Cre:ROSA26Ai9/+:Col2.3gfp and
Dmp1-Cre:ROSA26Ai9/+:Col2.3gfp mice. The ROSA26Ai9/+ transgene allows for the identification
of Ocn-Cre or Dmp1-Cre targeted cells as tdTomato+ cells19. The Col2.3gfp transgene allows for
the identification of osteoblasts and osteoblast progenitors as GFP+ cells293. In combination, we
can accurately sort Ocn-Cre or Dmp1-Cre targeted tdTomato+ GFP- stromal cells, excluding
osteoblasts. We will then perform RNA sequencing analysis on these two subsets of stromal cells
and compare their gene expression profiles. We will try to discover genes enriched in Ocn-Cre
targeted stromal cells that are potentially important for the regulation of B cells, especially
mature naive B cells and memory B cells. Among these genes, we will select candidates for
further functional tests, potentially using transgenic ablation models depending on their
availability. This future study may help improve our understanding of the heterogeneity of
stromal cells and the regulation of B cell development by specific stromal cells.
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5.3. Bone marrow cDCs regulate hematopoietic stem and progenitor cell trafficking
5.3.1. Summary
In Chapter 4, we assessed the role of bone marrow (BM) cDCs in the regulation of the
hematopoietic niche and HSPCs. Using Cx3cr1gfp mice, we identified cDCs in the bone marrow
and show that they localize to both sinusoidal and arteriolar regions. We further discovered that
the majority of these BM cDCs have a cDC2-like immunophenotype, but their gene expression
profile suggests that they are functionally different from conventional cDC2s in the spleen.
Interestingly, we also identified a similar population of BM cDCs in human bone marrow,
emphasizing the potential clinical relevance of this study. Using ablation models, we show that
the ablation of BM cDCs results in a secondary, non-cell autonomous loss of BM macrophages,
which have been previously reported to regulate HSPCs7. In addition, we show that the ablation
of BM cDCs induces HPSC mobilization, at least in part, through a macrophage independent
mechanism. Since HSPC mobilization is often associated with changes in the perivascular niche,
we characterized endothelial cells and discovered endothelial expansion following BM cDC
ablation. We also revealed a robust up-regulation of CXCR2 in sinusoidal endothelial cells and
the up-regulation of two major ligands of CXCR2 in the bone marrow, CXCL1 and CXCL2.
CXCR2 activation has been reported to induce vascular permeability and HSPC mobilization72,
thus we assessed the role of CXCR2 in the regulation of HPSC mobilization following BM cDC
ablation. We show that activation of CXCR2 in vitro induces vascular permeability and HSPC
migration. Moreover, we show that deletion of CXCR2 in non-hematopoietic cells significantly
attenuates HSPC mobilization after BM cDC ablation. Collectively, these data suggest that BM
cDCs play an important role in regulating HSPC trafficking, at least in part, through its
regulation of sinusoidal CXCR2 signaling and vascular permeability.
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5.3.2. Further assess the role of CXCR2 in endothelial cells
To examine the role of CXCR2 in the regulation of HSPC mobilization following BM cDC
ablation, we transplanted Zbtb46dtr bone marrow into irradiated Cxcr2-/- mice. The deletion of
CXCR2 is only restricted to non-hematopoietic cells in the bone marrow, including both
endothelial cells and stromal cells. It is possible that the attenuated HSPC mobilization following
BM cDC ablation may be a result of CXCR2 deletion in bone marrow stromal cells. To rule out
this possibility, we have an ongoing experiment using VEcad-Cre:Cxcr2flox/flox mice as the
recipients for Zbtb46dtr bone marrow transplant. This will allow us to restrict the deletion of
Cxcr2 to endothelial cells, excluding bone marrow stromal cells. We will then perform flow
cytometry and CFU-C tests to assess HSPC mobilization after BM cDC ablation in these VEcadCre:Cxcr2flox/flox mice.

5.3.3. How do BM cDCs regulate sinusoidal endothelial cells?
We have discovered that BM cDCs may regulate HSPC trafficking through its regulation of
sinusoidal CXCR2 signaling. However, how BM cDCs regulate sinusoidal endothelial cells
remains unknown. A prior study on BM macrophages suggests that they regulate HPSC
trafficking through mesenchymal stromal cells7. BM cDCs and BM macrophages share the same
myeloid origin, so we hypothesize that BM cDCs may also regulate mesenchymal stromal cells.
To test this hypothesis, we performed a pilot experiment in which bone marrow stromal cells
(BMSCs) were sorted from Zbtb46dtr bone marrow chimeras treated with 1 day of DT or PBS.
RNA microarray analysis on these cells suggested a potential functional change in BMSCs
following BM cDC ablation (Fig. 5.2A). Expression of CXCL1 and CXCL2 were up-regulated
in the whole bone marrow following BM cDC ablation to activate sinusoidal CXCR2 signaling
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(Fig. 4.4E&F). Surprisingly, the expression of CXCL1, but not CXCL2, was significantly
increased in BMSCs by more than 3-fold following BM cDC ablation (Fig. 5.2B&C), indicating
the partial involvement of BMSCs in the regulation of sinusoidal CXCR2 signaling. Collectively,
these preliminary data suggest that BM cDCs may regulate sinusoidal endothelial cells, at least
in part, through their regulation of BMSCs.
While BMSCs may regulate sinusoidal endothelial cells through their up-regulation of
CXCL1, it remains unknown how BM cDCs regulate BMSCs. Since the majority of BM cDCs
and BMSCs are both localized to the perivascular region, it is likely that the two cell populations
are in close proximity. Thus, it is possible that BM cDCs may directly regulate BMSCs through
the release of intermediate molecules or direct physical interaction. To test this possibility, gene
expression profiles from both cell populations will be compared to identify potential factor/
receptor pairs expressed by BM cDCs and BMSCs, respectively. In addition,
Zbtb46gfp:Cxcl1DsRed mice may be generated, in which BM cDCs are marked as GFP+ cells and
BMSCs are marked as DsRed+ cells. Bone sections from these mice may then be imaged to
check whether direct physical interaction exists between BM cDCs and BMSCs. In summary,
understanding the mechanisms involved in the regulation of BMSCs and sinusoidal endothelial
cells by BM cDCs will provide insights to the advancement in both basic and clinical research.

5.3.4. How do BM cDCs regulate BM macrophages?
In Zbtb46dtr bone marrow chimeras, the ablation of BM cDCs was observed 1 day after DT
treatment, and the ablation of BM macrophages was observed at day 2. Our data suggests that
BM cDC ablation may induce a secondary, non-cell autonomous loss of BM macrophages.
However, the mechanism involved in this regulation remains unclear. One possibility is that the
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death of BM cDCs will release signaling molecules, such as chemokines and cytokines, which
may induce cell death specifically in BM macrophages. Another possibility is that BM cDCs
may provide critical signals to support the survival of BM macrophages through their release of
survival factors or through direct physical interaction. To test these possibilities, gene expression
profiles from both BM cDCs and BM macrophages will be compared to identify potential
signaling pathways contributing to the survival or cell death of BM macrophages. In contrast to
direct regulation, BM cDCs may regulate BM macrophages indirectly through intermediate cells,
such as BMSCs. In addition to the above scenarios, BM cDCs and BM macrophages share the
same myeloid origin, thus the loss of BM cDCs may affect their common progenitor to undergo
a more cDC lineage committed differentiation, preventing the replenishment of BM
macrophages. Future research may include characterization of myeloid progenitors, BMSCs and
other cell populations in the bone marrow, before or after BM cDC ablation. Better
understanding of the mechanisms involved in the secondary loss of BM macrophages will likely
provide targets to the development of macrophage-depleting agents with significant clinical
applicability.

5.3.5. Assess the effects of BM cDC ablation on osteoblasts
Other than sinusoidal endothelial cells, we also assessed the effects of BM cDC ablation on
osteoblasts. Zbtb46dtr bone marrow chimeras were treated with DT for 6 days and we observed a
significant decrease in osteocalcin (Bglap2) mRNA level in the whole bone marrow (Fig. 5.3A).
Osteocalcin is mainly expressed by mature osteoblasts, thus our data suggests a suppression of
osteoblasts following BM cDC ablation. To test the effects of BM cDC ablation on osteoblasts,
Zbtb46dtr bone marrow was transplanted into Col2.3gfp mice in which osteoblasts are marked as
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GFP+ cells, followed by DT or PBS treatment 8 weeks after transplant. Using flow cytometry,
we quantified and sorted GFP+ osteoblasts from DT or PBS treated Zbtb46dtr bone marrow
chimeras. To our surprise, no significant difference was observed in the number of osteoblasts
after BM cDC ablation, compared to the control group (Fig. 5.3B). In addition, we tested the
expression of osteocalcin in sorted GFP+ osteoblasts and observed a significant decrease in the
osteocalcin mRNA level after BM cDC ablation (Fig. 5.3C). Collectively, our preliminary data
suggests that osteoblasts might be functionally suppressed following BM cDC ablation.
A prior study suggested that BM macrophage ablation might induce a functional
suppression of osteoblasts7. To test whether BM cDCs may regulate osteoblasts in a
macrophage-independent pathway, we compared bone marrow chimeras transplanted with
Zbtb46dtr, CD169dtr and CD169dtr:Zbtb46dtr bone marrow for the ablation of BM cDCs, BM
macrophages and both. The whole bone marrow osteocalcin mRNA levels in these mice suggest
that BM cDCs may regulate osteoblasts in a macrophage-independent pathway (Fig. 5.3D).
However, large variability exists in the osteocalcin mRNA level in CD169dtr bone marrow
chimeras, and further testing is necessary to support this hypothesis. One potential experiment is
to transplant CD169dtr bone marrow into Col2.3gfp mice and treat these chimeras with 6 days of
DT to ablate BM macrophages. We can then sort GFP+ osteoblasts and test their expression of
osteocalcin. In addition, it is more important to figure out the mechanism involved in the
regulation of osteoblasts by either BM cDCs or BM macrophages. These two populations mainly
localize to the perivascular region and osteoblasts localize to the endosteal region, thus
intermediate cells may be involved to relay the signals for their interactions. Further
characterization of osteoblasts using RNA-seq analysis before and after BM cDC ablation may
help detect potential pathways driving the suppression of osteoblasts. Potential factors activating

113

these pathways will then be tested in whole bone marrow or specific cell populations.
Osteoblasts are a critical component for osteogenesis and understanding the suppression of
osteoblasts will provide important insights to the development of potential therapies for bone
related diseases.

5.4. Conclusion
In this thesis, we further characterized the roles and functions of two bone marrow niche
components. In Chapter 2, we show that Ocn-Cre, Dmp1-Cre and Tagln-Cre transgenes target
different subsets of bone marrow mesenchymal stromal cells. We revealed that Ocn-Cre and
Dmp1-Cre target broader cell populations than previously appreciated, which should be
incorporated in the design of future study. We also suggest that Dmp1-Cre targeted stromal cells
may be enriched for osteoprogenitors. In Chapter 3, we tested the function of CXCL12 from
different subsets of stromal cells on B lymphopoiesis. We show that CXCL12 from Ocn-Cre
targeted stromal cells is particularly important for the regulation of mature naive B cells and
memory B cells, potentially through the regulation of their homing and/or retention. In Chapter
4, we assessed the role of BM cDCs in the regulation of the HSPCs. We show that BM cDC
ablation results in a secondary, non-cell autonomous loss of BM macrophages. We also
discovered that BM cDCs may regulate HSPC trafficking in a macrophage independent pathway,
at least in part, through its regulation of sinusoidal CXCR2 signaling and vascular permeability.
Collectively, this thesis study helps improve our understanding of the heterogeneity of stromal
cells and the regulation of B lymphopoiesis by different stromal cells. In addition, we propose a
novel bone marrow niche component that regulates HSPC trafficking. Although future research
is required to mechanistically study the stromal cells and BM cDCs, the results generated from
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this study provide insights that are important for the advancement in both basic and clinical
biology.
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5.5. Figures

Figure 5.1. CXCL12 expression in Ocn-Cre targeted stromal cells is important for the
regulation of T cells. A&B. Femurs were harvested from Ocn-Cre:Cxcl12flox/flox mice (A),
Dmp1-Cre:Cxcl12flox/flox mice (B), and Cxcl12flox/flox control mice (A&B). Bone marrow was then
analyzed using flow cytometry to quantify the number of different T cells, gated as T cell
receptor (TCR)+ cells. Sample size, n = 4-6 mice per group in all experiments. Data represent
the mean ±SEM, **P < 0.01; ***P < 0.001.
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Figure 5.2. The effects of BM cDC ablation on bone marrow stromal cells (BMSCs). Bone
marrow stromal cells were FACS sorted from Zbtb46dtr bone marrow chimeras treated with 1 day
of DT of PBS (n = 4 or 5 mice, respectively). Sorted cells were then used for RNA microarray
analysis. A. Gene expression profiles from the two conditions were compared and visualized
using t-Distributed Stochastic Neighbor Embedding (tSNE) analysis. B. The expression level of
CXCL1 mRNA in BMSCs was quantified by probe signal. C. The expression level of CXCL2
mRNA in BMSCs was quantified by probe signal. Data represent the mean ±SEM, **P < 0.01;
“ns” means no significant difference.
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Figure 5.3. The effects of BM cDC ablation on osteoblasts. A. The mRNA level of osteocalcin
(Bglap2) in whole bone marrow of Zbtb46dtr bone marrow chimeras, measured by RT-qPCR and
was normalized to the expression level of β-actin (n = 5 mice for both groups). Zbtb46dtr bone
marrow was transplanted into irradiated Col2.3gfp mice. After 8 weeks, these chimeras were
treated with DT or PBS for 6 days. B. The number of GFP+ osteoblasts was measured by flow
cytometry (n = 4 or 5 mice, respectively). C. GFP+ osteoblasts were sorted by FACS and their
mRNA level of osteocalcin was measured by RT-qPCR (n = 4 or 5 mice, respectively). Zbtb46dtr,
CD169dtr and CD169dtr:Zbtb46dtr bone marrow was transplanted into irradiated wildtype recipient
mice. After 8 weeks, these recipient mice were treated with 6 days of DT or PBS. D. The mRNA
levels of osteocalcin in whole bone marrow of these mice were measured by RT-qPCR (n =
6,6,5,4 mice respectively). Data represent the mean ±SEM, *P<0.05; **P < 0.01; ***P < 0.001;
“ns” means no significant difference. Samples were compared to PBS control group unless
otherwise indicated.
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